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ABSTRACT OF THE DISSERTATION
Evaluating the Structural and Functional Consequences of Traumatic Joint Injury and
their Relation to NF-κB in a Non-Invasive Model of Post-traumatic Osteoarthritis
by
Ian Matthew Berke
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2021
Professor Lori A. Setton, Chair
Post-traumatic osteoarthritis (PTOA) is a painful and debilitating disease of the
synovial joint, characterized by degenerative changes to various joint tissues following
traumatic joint injury. While several risk factors have been identified in the symptomatic
progression of PTOA following injury, inflammation and NF-κB mediated changes are
believed to significantly contribute to symptomatic joint dysfunction and pain. However,
the temporal presentation of these pro-inflammatory signals following clinically relevant
injury and their relationship to the development of symptomatic disease have not been
thoroughly investigated. Therefore, there exists a critical need to better understand how
these early inflammatory events following injury may contribute to the symptomatic
progression of PTOA.
In the first aim of this dissertation, the temporal relationship between NF-κB
activation and the development of pain-sensitivity related behaviors following joint injury
was evaluated in a non-invasive murine model of PTOA. Early activation of NF-κB
following traumatic knee joint injury was associated with several clinically relevant
changes in animal behavior including the acute presentation of allodynia, hyperalgesia,
xi

and transient alterations to weight bearing and ambulation/gait. Persistent unilateral
allodynia was observed up to 4 months following injury. Furthermore, early NF-κB
activation following injury was correlated with the severity of chronic allodynia and erosive
changes to articular cartilage. Data from this aim was used to define an early therapeutic
treatment window to test the efficacy of a locally delivered NF-κB inhibitor, PHA-408,
following joint injury.
Given the involvement of the NF-κB pathway in inflammation and in the
development of symptomatic PTOA, it was hypothesized that acute local pharmacologic
NF-κB inhibition might slow the progression of symptomatic PTOA following joint injury.
Findings in this aim highlighted the early chondroprotective effects of local PHA-408
following mechanical joint injury. Modest improvements in pain-sensitivity related
outcomes with repeated drug treatment were also observed. Nevertheless, local delivery
of PHA-408 failed to modify long-term degenerative changes to articular cartilage.
Engineered drug depots were also developed for the sustained release of PHA-408.
While these microparticle based depots showed the potential for sustained drug release
and inhibition of NF-κB in vitro, their use did not improve measured outcomes following
joint injury.
While the painful symptoms and debilitating impact of chronic conditions, such as
PTOA, may be apparent to the patients who suffer from the disease, many aspects of
sensory excitability which may contribute to pain, particularly in intact tissue, remain
unclear. Work in the final aim of this dissertation described the development of an ex vivo
imaging approach to functionally evaluate sensory neuron excitability within intact dorsal
root ganglion tissues. This method was capable of simultaneously assessing functional
xii

signaling dynamics in hundreds of neurons with single-cell resolution and was further able
to evaluate alterations to neural signaling following pharmacologic modulation and injury.
Overall, this dissertation serves to improve our understanding of the symptomatic
progression of PTOA following traumatic joint injury and highlights many of the challenges
of intra-articular drug delivery in the disease-modifying treatment of PTOA. Furthermore,
the novel imaging methods developed within this dissertation may help to elucidate the
structural and functional changes to musculoskeletal and peripheral nervous system
tissues following injury, respectively.

xiii

Chapter 1
Introduction
1.1 Osteoarthritis, a whole-joint disease
Osteoarthritis (OA) is one of the top three leading causes of disability in the United
States where it is estimated to affect over 30 million adults1–3. Globally more than 10% of
adults over the age of 60 suffer from symptomatic OA2,4. In these individuals severe
mobility limitations negatively impact quality of life and concurrently increase the risk for
other chronic conditions such as obesity and cardiovascular disease 5–8. In addition to the
direct impacts on quality of life, OA imparts a substantial economic burden on society.
Within the United States, arthritis-attributed medical expenditures and earnings losses
are estimated at over $300 billion annually9. These costs account for nearly 3% of the
United States gross domestic product9–11. Similar disease related economic impacts have
been reported globally12. While decades of research have identified several risk factors
associated with an increased incidence of OA including age, gender, activity level, prior
injury, obesity, and genetics, there remain no effective disease-modifying OA treatments
that halt or delay OA progression in a meaningful way6,13,14. Thus, there is great need for
further scientific inquiry that aims to better understand the temporal progression of
disease and develop efficacious disease-modifying treatment strategies for OA.
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OA has historically been characterized by the degeneration of articular cartilage.
In healthy joints, the highly organized and multi-phasic structure of articular cartilage
enables its unique functional properties (Fig. 1.1)8. Articular cartilage is nearly 80% water
by weight, the remainder of the tissue mainly consists of collagens and proteoglycans
which make up the extracellular matrix (ECM), and chondrocytes which sparsely populate
the ECM15. Collagen is the most abundant structural macromolecule in articular cartilage
and accounts for nearly 60% of tissue dry weight. Type II collagen represents roughly
90% of the collagenous ECM while minor constituents such as collagen types IX and XI
further contribute to ECM stability through collagen crosslinking 16. The highly organized
zonal microstructure of the collagenous ECM contributes to the anisotropic tensile
properties of articular cartilage16. The second most abundant class of macromolecule in
articular

cartilage

are

proteoglycans,

these

consist

of

negatively

charged

glycosaminoglycan (GAG) chains covalently bound to a protein core 5,8. The negative fixed
charged density of proteoglycans results in a swelling pressure which contributes to the
compressive properties of articular cartilage16. Chondrocytes represent roughly 2% of

Figure 1.1: Zonal cellular and microstructural composition of healthy articular cartilage. Figure
adapted from Buckwalter, Mow, and Ratcliffe. J Am Acad Orthop Surg. 1994.

2

total cartilage volume but are thought to be the primary mediators in cartilage
homeostasis17. Chondrocytes are largely responsible for the continued production of
ECM components such as collagens and proteoglycans which are required for healthy
cartilage structure and function18. Taken together, these highly organized constituents of
articular cartilage give rise to the tissue's unique functional properties which allow for
decades of near-frictionless joint function.
Although OA has historically been characterized as a degenerative disease of
articular cartilage, it is now well established that various joint tissues are altered in OA.
For this reason, idiopathic OA is more accurately described as a whole-joint disease (Fig.
1.2)19. For example, changes including synovial thickening and inflammation,
subchondral bone remodeling and osteophyte formation, and neo-vascular innervation of
joint tissues, may be observed in addition to articular cartilage degeneration 19–22. To this
date, the fundamental mechanisms that drive these changes in idiopathic OA remain
largely unknown.

Figure 1.2: Inflammation contributes to OA disease progression. Alterations to various joint tissues,
and an increase in pro-inflammatory signaling contribute to the development of OA. Figure adapted from
Kapoor+. Nat Rev Rheum. 2011.
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1.2 Post-traumatic Osteoarthritis
In post-traumatic osteoarthritis (PTOA) joint trauma (e.g. ligamentous rupture,
meniscal tear, hyper-physiologic loading) precipitates the accelerated degeneration of
joint tissues. Following traumatic joint injury, affected individuals have a nearly 10‐fold
increased risk of developing OA-like joint changes within 10 to 20 years of injury when
compared to their uninjured age-matched counterparts 23–28. While with idiopathic OA the
precise mechanical and/or biological changes that initiate disease are unknown, in PTOA
the triggering events that drive pathology are known injuries. As a result, there exists a
unique, early window of opportunity to study and treat acute changes that may ultimately
contribute to joint degeneration, pain, and loss of function post-injury.
Following traumatic joint injury, various disease-associated changes contribute to
the pathogenesis of PTOA (Fig. 1.3)28. Principally, hyper-physiologic loading has been
shown to alter chondrocyte viability, cell metabolism, and cartilage morphology within
hours of loading induced injury29–37. Additionally, shortly following injury increased levels
of pro-inflammatory cytokines, such as interleukin-1 beta (IL-1β), IL-6, IL-8, and tumor
necrosis factor-alpha (TNF-α), have been reported in synovial fluid and may remain
elevated for several months following joint trauma38–41. These pro-inflammatory mediators
contribute to a catabolic shift in the resident cells of the joint which may have not been
directly impacted by the initial injury28. Activation of catabolic gene sets within these cells
leads to increased levels of proteolytic and matrix degrading enzymes such as matrix
metalloproteinases (MMPs) and aggrecanases 42,43. These enzymes directly act to
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Figure 1.3: Temporal tissue and cellular level alterations following joint injury. Acute mechanical
joint trauma leads to a cascade of inflammatory and remodeling related cellular and tissue responses
which ultimately contribute to the development of PTOA. Figure adapted from Anderson+. J Orthop Res.
2011.

degrade the cartilage and subchondral bone ECM which, in turn, perpetuates the
progression of PTOA43–49. Knock-out studies have further highlighted these proinflammatory and catabolic mediators as significant contributors to disease progression
in PTOA50. Together these data suggest that manipulation of the joint microenvironment
following traumatic injury may impart protective effects on articular cartilage and other
joint tissues to slow the development of PTOA.

1.3 NF-κB activation in PTOA
The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)
pathway is a rapidly inducible inflammatory signaling pathway that has been identified as
a major player in the pathophysiology of several diseases 51. Dysregulation of NF-κB is
known to drive chronic inflammation in conditions such as irritable bowel syndrome,
chronic inflammatory airway disease, various cancer types, and rheumatoid arthritis 52–55.
Constitutive activation of NF-κB has long been implicated in the development and
maintenance of rheumatoid arthritis. Histologic studies of human rheumatic synovium
5

have shown chronically increased expression of phosphorylated p65 (P-p65) in synovial
tissues when compared to non-arthritic joints56,57. Animal models of inflammatory arthritis
have replicated these alterations seen in human joints and exhibit chronic activation of
the immune system, synovial hyperplasia, neovascularization and nerve fiber sprouting
in various joint tissues, and articular cartilage degeneration 58–62. Local NF-κB activation
in these models has also been correlated with the development of pain-sensitivity related
behaviors63. Pharmacologic NF-κB inhibition, however, has been shown to effectively
attenuate these pain-sensitivity related behaviors in inflammatory models 64–66.
While OA has long been classified as a non-inflammatory disease, recent studies
have highlighted the importance of NF-κB mediated signaling and inflammation in the
development of symptomatic PTOA following mechanical joint injury 67–69. While some
level of loading (e.g. mechanical, osmotic) helps to maintain cartilage homeostasis,
injurious loading has been shown to rapidly induce high levels of NF-κB activation in
chondrocytes70–73. It is thought this hyper-activation following injury contributes to a
persistent pro-inflammatory environment that initiates NF-κB signaling in other joint
tissues such as synovium42,70,74. Ultimately, these factors contribute to a pro-inflammatory
and catabolic feedback loop that drives the progression of PTOA.
Pre-clinical studies have shown NF-κB inhibition can serve to attenuate this
positive feedback loop and protect against joint destruction 75. The successful use of
selective IκB kinase 2 (IKK-2) inhibitors, such as 8-(5-Chloro-2-(4-methylpiperazin-1yl)isonicotinamido)-1-(4-fluorophenyl)-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide
(PHA-408), highlight the utility of NF-κB inhibition as a disease-modifying treatment
approach76,77. Specifically, PHA-408, a low molecular weight (560 Da), highly selective
6

inhibitor of IKK-2, has been shown to reduce the severity of inflammatory arthritis in
multiple preclinical animal models76. However, due to the ubiquitous nature of the NF-κB
pathway and associated off-target effects of systemic NF-κB inhibition, few drug
candidates have been successfully implemented in the clinic 78,79. Indeed, in some
treatment applications, pathway inhibition has been found to cause adverse effects such
as neutrophilia, fever, and increased IL-1 release 51,80–82. Nevertheless, local NF-κB
inhibition in PTOA remains a promising therapeutic approach due to the focal nature of
the disease. For example, a phase 1 clinical trial of the IKK inhibitor, SAR113945,
improved pain scores following intra-articular injection in patients with OA. Unfortunately,
a phase 2a trial failed to show efficacy83. In spite of this result, there is considerable
evidence supporting the use of NF-κB pathway inhibitors in the treatment of OA 68,75,76,84–
87.

1.4 Assessing the symptomatic progression of OA
Although symptomatic OA imparts a substantive social and financial burden on
society, limited research has focused on the mechanisms contributing to pain in the
disease state88. Clinically, efforts have largely aimed to understand structural joint
changes using radiographic based assessments89. While these methods are valuable for
disease staging, by themselves they provide no insight into pain or joint function.
Standardized functional and symptomatic self-reported scoring systems (e.g.
Western Ontario and McMaster Universities Arthritis Index (WOMAC) and Knee injury
and Osteoarthritis Outcome Score (KOOS)) have helped to better quantify the
symptomatic effects of OA90. Studies that have used these scoring systems paired with
clinical imaging measures have provided valuable insight into the relationships between
7

joint structure changes, such as synovitis and the formation of bone marrow lesions, and
symptomatic OA91,92. However, these methods still fail to directly assess the molecular
and cellular changes contributing to symptomatic OA.
The use of OA animal models for the study of symptomatic OA serves to address
some limitations of clinical studies. Principally, animal models allow for the coincident and
well controlled interrogation of molecular, cellular, structural, and functional sensitivity
changes within the same subject93. This approach, which may be infeasible in a clinical
setting, allows for a more comprehensive understanding of the factors influencing
symptomatic disease progression. Indeed, OA animal models have replicated many of
the structural changes seen in symptomatic OA (e.g. synovitis, joint effusion, bone
marrow lesions, sensory nerve fiber innervation)58,94–100. Furthermore, these structural
changes observed in OA models have been associated with the development of clinically
relevant symptoms such as mechanical allodynia and functional limitations to
ambulation101–103. Animal models have also helped uncover molecular and functional
signaling changes in the peripheral nervous system which are thought to contribute to the
painful symptoms of OA104,105. Nevertheless, further research into the temporal
progression of pain-sensitivity related behaviors and functional disability in OA animal
models may provide an improved basis for the treatment of symptomatic disease.
Most widely utilized small animal models for the study of OA employ surgical
means to induce joint destabilization, thus they are more accurately categorized as PTOA
models106. Surgically induced injuries, such as those used by the destabilization of the
medial meniscus (DMM) or anterior cruciate ligament transection (ACLT) models,
ultimately lead to reproducible and progressive degeneration of joint tissues over time 106–
8

108.

However, the temporal development of symptomatic disease, with implications for

altered pain-sensitivity related behavior, remains unclear in these models. While
standardized surgical procedures are described in the literature, surgically induced
injuries can be technically challenging and rely on surgical expertise for consistent
outcomes30. This may, in part, explain the variability in the onset and severity of painsensitivity related behavioral alterations observed in surgical models109–114. Furthermore,
surgical incision related factors cannot be ruled out as contributors to alterations in painsensitivity related behaviors, particularly at acute timepoints115,116. Consequently, surgical
PTOA models may be limited in their ability to study pain-sensitivity related behavioral
alterations shortly following injury113,116–118.
Non-invasive models of PTOA allow for the study of joint injury triggered alteration
to pain-sensitivity behaviors without the confounding nature of a surgical incision. These
models also enable fine-tune control of injury severity depending on loading configuration,
duration, and magnitude29,119–121. To date, few studies have focused on the
characterization of symptomatic disease progression following these non-invasive
injuries, and those that have, utilize differing metrics of pain-sensitivity and behavior 69,122–
126.

For example, Anderson and colleagues have shown transient gait alterations following

a non-invasive knee joint injury, however, no further changes in animal behavior were
observed126. Others have demonstrated unilateral changes to allodynia, hyperalgesia,
and static weight bearing shortly following non-invasive injury, but the temporal
progression of these changes remains unclear and largely unstudied 69,124. For these
reasons, further research to interrogate the temporal presentation of pain-sensitivity
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related behaviors following non-invasive joint injury would add value to our current
understanding of the symptomatic progression of PTOA.

1.5 Current treatment strategies for OA
There are currently no clinically available therapies that safely treat both the
symptomatic and structural aspects of OA 127,128. Palliative treatments, such as nonsteroidal anti-inflammatory drugs (NSAIDs), are the most widely utilized front line
therapies to treat the symptoms of OA129. Although NSAIDs may elicit short-term
improvements in pain and function, their chronic usage can lead to cardiovascular and
gastrointestinal complications130,131.
When

NSAIDs

provide

no

palliative

benefit,

intra-articular

corticosteroid

administration is a common next step in treatment 132. While this approach has shown
some efficacy in reducing acute pain and inflammation, long-term outcomes are not
improved by intra-articular corticosteroid delivery133. This may be due to the rapid
clearance of low molecular weight solutes from the joint, intra-articular half-lives of
corticosteroids are rarely found to exceed 12 h134. Some data also suggest high
corticosteroid concentrations may negatively impact cartilage homeostasis by reducing
chondrocyte ECM biosynthesis135.
Viscosupplements, such as hyaluronic acid derivatives, have a long history of
clinical use to treat symptomatic OA, and several formulations (e.g. Gel-One, Euflexxa,
Orthovisc) have been granted FDA approval for intra-articular delivery 136,137. These
viscosupplements are thought to improve synovial fluid quality and reduce frictional
coefficients in the joint138. High molecular weight hyaluronan has also been shown to
display anti-inflammatory and immunosuppressive properties 139,140. This is in contrast
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with the inflammatory and immune-activating properties of low molecular weight
hyaluronic acid fragments141. Despite the short-term palliative effects of these treatments,
they still fail to substantively modify the long-term structural and symptomatic progression
of OA132,142. Given the lack of success for these current OA treatment strategies, there is
an unmet need for the further development of disease-modifying OA drugs 128.

1.6 Intra-articular drug delivery and clearance
While systemic delivery of disease-modifying OA drugs has shown efficacy in many
pre-clinical studies, systemic drug administration does not ensure ideal drug
bioavailability in the affected joint134. Molecular entry into the joint space is sizedependent. Smaller molecules (<10kDa) may diffuse through synovial capillaries and
synovial intima and equilibrate within the synovial fluid (Fig. 1.4)143. Larger molecules
undergo size-dependent sieving and have reduced access to the joint space 144,145.
Locally delivered treatment, via intra-articular injection, serves to maximize drug
bioavailability within the diseased joint. The increased bioavailability of locally

Figure 1.4: Factors influencing molecular efflux from the joint. Alterations to composition and
structure of synovial tissues and cartilage contribute to altered clearance kinetics from OA joints. Figure
adapted from Brown+. Acta Biomat. 2019.
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administered drugs enables an overall reduction in drug dose which, in turn, reduces
systemic exposure and the risk for off-target effects 146.
Following size-dependent entry into the joint, molecular efflux shows a similar size
dependence. Small molecules, like acridine orange (370 Da), have short intra-articular
half-lives (t1/2~30 min), whereas larger macromolecules such as hyaluronic acid (3.0x10 6
Da) are cleared more slowly (t1/2~24 h)147–151. Intra-articular half-lives for NSAIDs and
soluble steroids cluster around 1 to 4 h. These values illustrate the challenges facing
intra-articular therapy, especially for chronic or progressive conditions where sustained
drug concentrations are required for therapeutic efficacy 152.
There are however various biophysical phenomena that can be exploited to
overcome some of the hurdles of intra-articular drug delivery 153. For example, recent
research has revealed the importance of charge-based interactions between locally
delivered molecules and negatively charged cartilage ECM. Bajpayee and Grodzinsky
have shown positively charged macromolecules exhibit enhanced molecular diffusivity
and residence times within healthy cartilage ECM154. This effect of cationic potential in
cartilage targeting is not without its limitations 155. Specifically, supercharged-GFP
variants, modified to have increased cationic electrostatic potential, had improved
cartilage permeability at lower, but non-zero, net charges. Interestingly, chondrocyte
uptake was enhanced in variants with increased cationic charge 156. These results suggest
drug biophysical properties should be carefully considered when assessing the joint
tissue and resident cell targeting potential of intra-articular therapeutic approaches 157.
Disease related changes to other joint structures also play a role in the clearance
of locally delivered molecules. Most notably, synovial thickening is thought to reduce
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molecular efflux from the intra-articular space22. Despite the presence of increased
vascularization in arthritic joints, literature consistently suggests functionally impaired
clearance of multiple solutes20,147,158–160. Radiolabeling studies were the first to highlight
these alterations with disease and revealed significantly reduced intra-articular clearance
rates of

123I

and

131I-labeled

human serum albumin (66.5 kDa) in patients with OA 159,161.

Similar disease associated changes to intra-articular clearance have been observed in
PTOA animal models147,160. Altered lymphatic structure and function have also been
implicated in modulating intra-articular clearance in diseased joints 162. Surprisingly,
functional deficits in lymphatic mediated clearance are despite increased lymphatic vessel
formation reported in arthritic joints163–167. Research by Doan and colleagues has also
demonstrated the clearance modulating role of knee joint innervating venous and
lymphatic vascular structures in the absence of disease 151.
Taken together, these findings reveal the benefit of intra-articular drug delivery for
the treatment of OA and further emphasize the wide variety of factors that influence
molecular transport from arthritic joints. When assessing and/or modulating molecular
efflux from the joint, special care must be taken in considering the full array of parameters
that are known to impact intra-articular transport phenomena.

1.7 Engineered drug delivery strategies for OA
Engineered drug delivery strategies primarily seek to overcome the clearance
based limitations of small molecule and protein delivery to the joint. Historically, hydrogel
and particle based drug depots have been the most widely utilized carriers for intraarticular therapies152,168. These approaches heavily rely on the fundamental molecular
weight based clearance properties that largely govern molecular efflux from the joint 148.
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Despite the seeming simplicity of this phenomenon, its exploitation has resulted in
increased intra-articular residence times for locally delivered drugs through the use of
particle and hydrogel based sustained release drug depots138,169,170. Clinical application
of these depots (e.g. Lipotalon, Zilretta/FX-006) have prolonged the palliative effects of
locally delivered drugs138,171–175.
While a wide variety of drug delivery depots have been shown to improve intraarticular residence times and the subsequent therapeutic efficacy of locally administered
drugs, polymeric microparticles are generally thought to be better suited for intra-articular
delivery due to their high degree of tunability176. Specifically, polymeric particles can be
synthesized with larger diameters, when compared to lipid or dendrimer based particles,
which help to increase their passive size-based retention within the joint 170,177.
Furthermore, synthetic and natural polymeric depots can deliver a diverse set of cargo
(e.g. siRNA, virus, protein, imaging agents, small molecules) with a high degree of control
over drug release and particle degradation kinetics178.
The research in this dissertation employs both synthetic and natural polymeric
microparticles synthesized with amphiphilic PEG-block-PLGA copolymer and silk fibroin
(SF), respectively. Prior work has shown PEG-PLGA drug depots can efficiently
encapsulate small hydrophobic drugs and persist in the joint for up to 4 weeks following
intra-articular injection179,180. SF, derived from the Bombyx mori silkworm, has high
biocompatibility, non-immunogenic degradation products, and is FDA approved in some
biomedical applications181. Depending on processing conditions, SF biomaterial
properties (e.g. pore size, stiffness, beta-sheet content, degradation kinetics) can be finetuned for use in different applications and have shown the ability to entrap and release
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compounds of various physiochemical properties182,183. Specifically, low molecular weight
hydrophobic compounds, such as Rhodamine B, have been previously incorporated into
SF microparticles with high loading efficiencies and favorable extended release
profiles183. Furthermore, our group has shown SF microparticles serve to increase intraarticular dwell times of low molecular weight cargo 184. Given these characteristics of PEGPLGA and SF microparticles, and their successful use in sustained release drug depot
applications, they were selected as favorable polymeric microparticle candidates for the
sustained release of the hydrophobic small molecule IKK-2 inhibitor, PHA-408.

1.8 Sensory neuron signaling and imaging
While functional assessments of peripheral sensitivity (e.g. von Frey and
Hargreaves tests) are valuable in assessing pain-sensitivity changes resulting from
disease or injury, these methods alone do not provide direct insight into functional
signaling alterations at the cellular level185–187. Sensory neurons, which consist of a cell
body/soma, axon, and peripheral axon terminals/receptors, innervate peripheral tissues
and are responsible for receiving and transmitting sensory input 188. These afferent fibers
relay unipolar sensory signals in response to thermal, chemical, pressure, and noxious
stimuli through spinal nerves to the dorsal root ganglion (DRG)189. DRGs contain the cell
bodies of sensory neurons which further transmit sensory stimuli to the dorsal horn of the
spinal cord190. Although the basic structure and function of DRG neurons have are well
characterized, the mechanisms by which sensory stimuli are encoded and transmitted by
these cells remain unclear191. Therefore, a better understanding of signal transduction
within DRG neurons is required.
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Typical in vitro methods for the functional assessment of DRG neuron excitability,
such as whole cell patch clamping, require surgical removal of the DRG via axotomy
followed by subsequent enzymatic and mechanical disruption 192,193. While this is useful
for preparing DRG neurons for monolayer culture, such techniques substantially modify
the native cellular microenvironment by reducing physiologically relevant cell-cell and cellmatrix interactions that modulate cellular excitability in vivo194,195. Furthermore, patch
clamping and similar current or voltage querying methods are limited to measuring
changes in individual cells at any one time191,196. While similar approaches, such as extracellular single unit recordings, may assess cellular in situ electrophysiology with minimal
tissue disruption, these techniques still have limited throughput which may impact their
ability to accurately represent heterogeneous cell populations 189. Nevertheless, these
tissue preparations and electrophysiological methods remain the gold standard for
understanding ion channel dynamics191.
Recent advancements in imaging have allowed for the simultaneous capture and
analysis of ion and ion channel dynamics in diverse cell populations 197. Fura-2 has been
the most widely utilized fluorescent dye for this purpose198. However, Fura-2 and similar
ultra-violet excited dyes are often not suitable for long-term or repeat analysis of ion
dynamics due to ultra-violet induced phototoxicity197,198. Additionally, the use of
exogenous fluorescent dyes are somewhat restricted in intact tissues due to dye loading
and diffusion based limitations197. The development of genetically encoded calcium
indicators (GECIs), such as those from the GCaMP family, enable spatiotemporal control
of cell-type specific indicator expression 199. These genetically encoded indicators of
neuronal activity when paired with high speed imaging allow for the study of cell signaling
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dynamics with minimal chemical or mechanical disturbance to the native cellular
environment200. The research in this dissertation uses these recent advances in imaging
and genetic techniques to develop a novel imaging modality to assess the excitability of
sensory neurons within acutely isolated intact DRG tissues.

1.9 Dissertation structure and aims
1.9.1 Aim 1: NF-κB-mediated effects on behavior and cartilage
pathology in a non-invasive loading model of post-traumatic
osteoarthritis (Chapter 2)
To better understand the temporal activation of NF-κB and its relation to the
development of symptomatic PTOA following knee joint injury, a murine non-invasive
tibial loading model of PTOA was used. Emphasis was placed on outcome measures that
track longitudinal changes to pain-sensitivity related behavior as well as concurrent NFκB activation via in vivo bioluminescent imaging. Findings in Chapter 2 highlighted the
temporal relationship between joint injury, NF-κB activation, and the development of painsensitivity related behaviors. In addition, Chapter 2 results were used to define a
therapeutic treatment window, which in turn was used to test the therapeutic efficacy of
locally delivered PHA-408 following joint injury in Aim 2.

1.9.2 Aim 2: Intra-articular delivery of an NF-κB inhibitor in a noninvasive loading model of post-traumatic osteoarthritis (Chapter
3)
Given the involvement of the NF-κB pathway in the development of PTOA, it was
hypothesized that acute local pharmacologic NF-κB inhibition would slow the progression
of PTOA following joint injury. In Chapter 3 the same longitudinal outcome measures of
pain-sensitivity and NF-κB activation, described in Chapter 2, were used to evaluate the
efficacy of locally delivered PHA-408 following joint injury. Work also characterized and
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explored the effectiveness of two drug depots for the sustained release of PHA-408.
Findings in Chapter 3 highlighted the early chondroprotective effects of local PHA-408
administration following mechanical joint injury. Modest improvements in pain-sensitivity
related outcomes with repeated drug treatment were also observed. Nevertheless, local
delivery of PHA-408 failed to prevent the long-term degeneration of articular cartilage.
While engineered drug depots showed the potential for sustained drug release, their use
did not improve measured outcomes following joint injury.

1.9.3 Aim 3: Electric field stimulation for the rapid functional
assessment of alterations to intact dorsal root ganglion neuron
excitability (Chapter 4)
Sensory neuron signaling is required for the sensation of physical stimuli. Yet,
many aspects of sensory excitability, particularly in intact tissue, remain unclear. The
primary goal of this aim was to describe and validate the development of an ex vivo
imaging approach to functionally assess sensory neuron excitability within intact dorsal
root ganglion tissues. Results showed the described novel imaging method was
reproducible and that cells responded to applied electric field amplitudes in a voltage
dependent manner. Electric field stimulated responses were also shown to be, in part,
driven by tetrodotoxin-sensitive voltage-gated sodium channels. Finally, this novel
method was used in a proof of concept study to assess excitability of sensory neurons
following peripheral nerve injury. With injury, neurons had reduced sensitivity to electric
field mediated stimuli, furthermore, ex vivo observations were correlated with in vivo
assessments of peripheral sensitivity. Ultimately, these methods may help to further
interrogate the neurophysiologic basis of sensory neuron signaling and guide the
development of improved therapeutic approaches in ion channel mediated diseases.
18

Chapter 2
NF-κB-mediated effects on behavior and cartilage
pathology in a non-invasive loading model of posttraumatic osteoarthritis
2.1 Introduction
As discussed in Chapter 1, OA is one of the leading causes of disability in the
United States. Approximately 12% of all patients seeking treatment for symptomatic OA
have had prior joint trauma1. Following traumatic joint injury, roughly half of affected
individuals will develop post-traumatic osteoarthritis (PTOA) within 10-20 years 24,26.
Pathological changes following traumatic joint injury are varied but may include alterations
to joint mechanics, inflammation, cell death, and altered extracellular matrix properties 28.
Many of these changes, which occur shortly following injury, are thought to play a pivotal
role in initiating the long-term development of symptomatic PTOA 30,39–41. A better
understanding of these acute post-injury changes, and their relationship to the
development of symptomatic disease, may help to define optimal strategies for
therapeutic intervention in PTOA.
Pre-clinical animal models of arthritis serve as a useful tool for understanding the
pathophysiology of disease108,201,210,202–209. Generally, these models may be classified by
their means of initiation which may include chemically, surgically, non-invasively/overuse,
and genetically induced arthritis30,106. Within each of these categories, there are an
assortment of models that produce arthritis at varying severities and over differing
timescales. In this work, we have chosen to use a non-invasive loading model of PTOA
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to study behavioral changes that occur following an acute traumatic joint injury. This
model was selected for its consistent and reproducible injury, disease-severity tunability
(dependent on loading parameters), and the non-invasive nature of the procedure.
Furthermore, the mechanism of injury initiation, overloading induced joint instability, is
relevant to a large number of clinical PTOA cases.
Loading models accurately capture many of the features of traumatic joint injury
which may lead to PTOA in humans30. Following injurious tibial compression, knee joints
exhibit

rapid

alterations

to

joint

biomechanics,

synovium,

cartilage,

and

bone29,30,42,73,207,208,211,212. Knee joint loading has been shown to trigger robust NF-κB
activation in cartilage and synovium within hours of injury68. Inflammatory signaling
mediated via NF-κB is thought to play a crucial role in the development of PTOA 51,67,75.
NF-κB activation following injury has also been directly implicated in the development of
chronic pain-related sensitivity63,66,213–215. Thus, further work to define the role of NF-κB
signaling in the symptomatic progression of PTOA is warranted.
In this chapter, our goal was to longitudinally examine the relationships between
the development of pain-related behavioral changes and NF-κB activation in vivo in a
non-invasive murine tibial compression model of PTOA.
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2.2 Methods
2.2.1 Animal and injury model
All procedures were performed with approval of the Washington University
Institutional

Animal

Care

and

Use

Committee.

Transgenic

FVB.Cg-Tg(HIV-

EGFP,luc)8Tsb/J mice (Fig. 2.1A) (The Jackson Laboratory, Bar Harbor, ME) were
acquired (male, 9-12 weeks of age) and acclimated to testing equipment for 1 week 216.
Mice in cohort 1 were randomly assigned to sham control (CTRL, n=5) or joint injury (INJ,
n=6). An additional group of mice (male, 9-12 weeks of age, n=5/group) were used to
assess how knee joint injury influenced gait (section 2.2.8). To induce joint injury, mice
were anesthetized under isoflurane (1-3% inhalation, 2 L/min oxygen) and right knees
were loaded as previously described by Rai and colleagues on a materials testing system
(Instron ElectroPulse E1000, Norwood, MA)29. Briefly, tibiae were positioned vertically
with the knee upwards in deep flexion between custom-made fixtures and were then
subjected to 60 cycles of 12 N axial compressive load (54 N/sec with 10 sec hold at 0.5
N between cycles). This protocol reproducibly induced a sudden drop in the axial force
recorded on the time-force curve and increased anterior-posterior joint laxity (Fig. 2.1B,C)
via a joint laxity test in a separate cadaveric test cohort (Appendix A, Supplementary
Methods)29,119,207. CTRL animals were placed within the test frame and their knees were
subjected to 10 min of static axial compressive load at 0.5 N. Animals were returned to
their home cage and allowed to freely ambulate upon recovery.
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2.2.2 In vivo luminescence imaging of NF-κB activity
To assess local NF-κB activation following joint injury, in vivo bioluminescent
imaging was performed. At each imaging timepoint (Fig. 2.1D) mice received an injection
of D-luciferin (150 mg/kg i.p., Sigma-Aldrich, St Louis, MO). Mice were anesthetized 10
minutes following D-luciferin injection and whole-body luminescent images were acquired
with an in vivo imaging system (10 sec exposure, IVIS 50, PerkinElmer, Waltham, MA).
NF-κB-driven luminescence was quantified in both ipsilateral and contralateral knees
within an 8x10 mm elliptical region of interest (ROI) that was placed around the knee joint.

Figure 2.1: Study design. (A) Representative NF-κB response element of FVB.Cg-Tg(HIV-EGFP,
luc)8Tsb/J mice. (B) Custom-made mount for in vivo loading to induce non-invasive joint injury and
corresponding time versus force and displacement curves showing one cycle of compressive loading
with characteristic one-time mid-cycle drop in the time versus force curve coinciding with ligament injury.
(C) Injured joints have increased anterior-posterior joint laxity as measured by a joint laxity score. (D)
Study timeline showing repeated imaging and behavioral assessments. Mean±SD (n=10/group), Mann
Whitney test; ***=p<0.001.
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2.2.3 Pain-related hindpaw sensitivity
Mechanical allodynia was evaluated in both the ipsilateral and contralateral
hindpaws using von Frey filaments. Filaments ranging from 0.02-2.0 g were applied to
the plantar region of a stationary, non-rearing, animal using the Chaplan “up-down”
method186,217. Briefly, the starting filament (0.4g) was applied for 3 sec or until the animal
had a positive paw-withdrawal response (guarding, paw flick, lick, and/or jump seen in
Fig. 2.2A). Based on the prior response either the next weaker (positive response) or
stronger (negative response) filament was then applied. Following the first change in
response four additional filament applications were applied (using the up-down method).
Provided no change in response occurred, filaments were applied until the weakest or
strongest filament produced either a positive or negative response, respectively.

Figure 2.2: Graphical overview of select behavioral assessments. Representative still images of
positive withdrawal responses (arrowpoint) for von Frey (A) and peripheral thermal sensitivity (B)
assessments. (C) Schematic of murine gait arena, enables simultaneous recording of sagittal and
ventral views.
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2.2.4 Pain-related hyperalgesia
The threshold for contact hyperalgesia was tested at the knee joint using a small
animal algometer (SMALGO, Bioseb, Vitrolles, FRA). Mice were scruffed with one hand
and the hindpaw was held with the knee at a ~30° flexion angle. The tip of the SMALGO
force transducer was applied to the lateral aspect of the knee at ~30 g/sec until the animal
showed an escape response (flinch, head jerk, and/or squeak, to a maximum of 400 g) 218.
Three independent measurements were obtained and averaged for each hindlimb on
each mouse on all behavioral testing days. One animal within the INJ group showed
extreme hypersensitivity/discomfort to light knee palpation on days 2 and 8 following
loading and thus was excluded from hyperalgesia testing on those days.

2.2.5 Hindpaw thermal sensitivity
Mice were gently scruffed and the plantar side of the tested paw was placed on a
hot/cold plate (50/0°C, BIO-CHP, Bioseb) while the other paw was placed on a room
temperature plexiglass surface at the same height. Mice were held stationary until a clear
paw withdrawal occurred or a 20 or 30 sec threshold was reached on the hot and cold
plate, respectively (Fig. 2.2B)219. Latency to withdrawal was recorded and three
independent measures were collected for each hindpaw at each temperature. Animals
were allowed a one minute recovery period between consecutive hindpaw
measurements.

2.2.6 Static weight bearing
Mouse hindlimb static weight bearing was measured using an incapacitance meter
(BIO-SWB-TOUCH-M, Bioseb). Mice were placed in a small transparent enclosure with
their hindpaws resting on two independent force plates and their forepaws resting on an
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angled wall of the enclosure. Independent force measurements from both hindpaws were
collected simultaneously over a 3 sec interval. Three independent measurements were
obtained and averaged for each mouse on all behavioral testing days.

2.2.7 Spontaneous activity
Freely selected activity was assessed by tracking mouse movement within a
custom arena (40 cm x 40 cm x 40 cm, matte black P95 acrylic, TAP Plastics, Stockton,
CA) for 30 min during the dark portion of a 12 h light-dark cycle; all tracking was performed
without the presence of investigators or other personnel and with illumination by red
light220,221. Movement was recorded (Sony Handycam HDR-CX405, Sony Corp, New
York, NY) and each 30 min video was analyzed (EthoVision, Noldus, Wageningen, NLD)
to determine the difference in distance traveled, average speed, and percent time
stationary from baseline for each animal.

2.2.8 Spatiotemporal gait testing
A separate cohort of mice underwent longitudinal spatiotemporal gait testing to
determine how non-invasive knee injury alters joint function during free, unprompted,
ambulation. A modified custom-built gait arena (Fig. 2.2C; 76 cm long x 7 cm wide x 13
cm tall, extruded acrylic, TAP Plastics) was used to acquire spatiotemporal gait data as
described previously222–224. During gait collection, animals voluntarily explored (i.e. not
forced/prompted) the arena at self-selected velocities and recordings were collected with
a high-speed video camera (FASTCAM Mini UX50, Photron, San Diego, CA) at 1000
frames per sec. Trials with consistent walking speed and at least three complete gait
cycles were analyzed. Longitudinal gait data were collected 2, 7, 14, and 36 days
following joint injury. Spatiotemporal gait parameters including duty factor, duty factor
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imbalance, and spatial symmetry were calculated using Automated Gait Analysis Through
Hues and Areas (AGATHA) open source software223–226.

2.2.9 Histology
Mice were euthanized at the terminal timepoint (113 days) and ipsilateral knees
collected for histology. All knees were fixed in 4% paraformaldehyde for 48 h, decalcified
for 72 h using ImmunocalTM (Fisher Scientific, Waltham, MA), immersed in 30% w/v
sucrose for 24 h, and cryoembedded in Tissue-Tek ® O.C.T. (Sakura Finetek, Torrance,
CA). Serial coronal sections (8 µm) of ipsilateral knees from all groups were acquired,
and one section representing the most severe evidence of arthritic changes was chosen
for staining with H&E, Safranin O, and fast green. Stained sections were graded to
consensus by two blinded graders using the Osteoarthritis Histopathology Assessment
System (OARSI) within the medial and lateral femoral condyle (MFC/LFC) as well as the
medial and lateral tibial plateau (MTP/LTP) 227.

2.2.10 Statistical analysis
Statistical analyses were performed using GraphPad Prism 8.0 (GraphPad
Software, La Jolla, CA). A repeated measures two-way ANOVA with Bonferroni’s posthoc was used to test for differences between CTRL and INJ at each timepoint for all
longitudinal measures. In vivo imaging and 50% withdrawal threshold data were logtransformed (base 10) to better meet ANOVA assumptions. A repeated measures twoway ANOVA with Bonferroni’s post-hoc was used to test for differences in cartilage
OARSI scores at each cartilage site between CTRL and INJ groups. The relationship
between NF-κB luminescence and allodynia was tested via Pearson correlation on logtransformed (base 10) data (Appendix A, Supplementary Methods). For velocity
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dependent gait parameters a linear regression was fit to CTRL animals and residual
values were calculated225,226,228,229. Following, a two-way ANOVA with Bonferroni’s posthoc was used to test for differences in gait outcomes at each timepoint between CTRL
and INJ groups. Statistical significance was set at p < 0.05.
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2.3 Results
2.3.1 Joint injury leads to increased NF-κB-driven luminescence
A transient increase in NF-κB-driven luminescence was observed in INJ ipsilateral
limbs when compared to ipsilateral limbs from CTRL mice on days 1 and 3 following joint
injury (Fig. 2.3A,B). Within injured ipsilateral limbs, luminescence intensity peaked within
the knee ROI on day 3 and decreased thereafter. There was no evidence of differences
in NF-κB-driven luminescence in the contralateral joints between CTRL and INJ animals.

2.3.2 Joint injury alters sensitivity to evoked mechanical but not
thermal stimuli
Non-invasive joint injury resulted in several changes to pain-related sensitivity and
behavior in mice. Increased hindpaw sensitivity to mechanical stimuli (allodynia) was
observed following joint injury as evidenced by a reduced 50% hindpaw withdrawal
threshold at days 2, 8, and 15 following joint injury (Fig. 2.3C). Following day 15, the 50%
withdrawal threshold in the INJ group returned to levels that were consistent with those
in the CTRL group, although a reduced 50% hindpaw withdrawal reemerged in the INJ
group on day 113. There were no differences between 50% withdrawal thresholds of
CTRL and INJ groups within contralateral hindpaws. Within a 4 week period following
loading, several animals in INJ group exhibited promoted guarding in their ipsilateral
hindpaw. In some animals, this behavior persisted for the remainder of the study.
Furthermore, increased NF-κB signaling was associated with reduced withdrawal
thresholds in the first week of the study (Fig. 2.3D).
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Figure 2.3: Non-invasive joint injury alters NF-κB signaling and sensitivity to mechanical stimuli.
(A and B) Increased luminescent signal (arrowpoint) was apparent in ipsilateral INJ knees 1 and 3 days
following joint injury (C=contralateral). (C) Mice in the INJ group had increased mechanical sensitivity in
their ipsilateral hindpaw following injury. (D) Increased NF-κB signaling in joints was associated with
reduced withdrawal thresholds in the first week of the study. (E) Mice in the INJ group had a reduced
threshold to noxious mechanical stimuli in their ipsilateral, but not contralateral, knee following joint
injury. Repeated measures two-way ANOVA w/ Bonferroni’s post-hoc; *=p<0.05, **=p<0.01,
***=p<0.001, ****=p<0.0001.

Joint injury also led to transient hyperalgesia in the ipsilateral limbs of animals in
the INJ group; reduced hyperalgesia thresholds were observed on days 2 and 8 following
joint injury compared to animals in the CTRL group (Fig. 2.3E). There were no observed
differences in hyperalgesia thresholds for contralateral limbs between mice in the CTRL
and INJ groups.
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Withdrawal latency from a hot (Fig. 2.4A) or cold (Fig. 2.4B) thermal stimuli at the
hindpaw were not found to differ between CTRL and INJ groups. Within groups, response
latencies were similar in ipsilateral and contralateral limbs (Appendix A, Fig. A.1),
generally, latencies were also found to decrease over the course of the study.

Figure 2.4: Thermal sensitivity at the hindpaw. Non-invasive knee joint injury did not alter sensitivity
to a hot (A, 50°C) or cold (B, 0°C) stimulus at the hindpaw. C=contralateral, repeated measures twoway ANOVA.
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2.3.3 Joint injury alters non-evoked behaviors
Mice in the INJ group exhibited reduced weight bearing on their ipsilateral hindlimb
on days 2 and 8 following joint injury (Fig. 2.5). For the remainder of the study weight
bearing between CTRL and INJ groups were equivalent.

Figure 2.5: Static weight bearing. Static weight bearing on the ipsilateral limb was transiently reduced
following knee joint INJ. Mean±SD, repeated measures two-way ANOVA w/ Bonferroni’s post-hoc;
****=p<0.0001.

Animals in the INJ group showed a trend of reduced freely selected activity on day
2 following joint injury, corresponding trends in average speed and percent time stationary
were also observed (Fig. 2.6A-D). Ambulatory levels within individual mice, particularly
within the CTRL group, were quite variable throughout the study, additionally, ambulation
decreased with time within 30 minute open field trials (Appendix A, Fig. A.2).
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Figure 2.6: Non-invasive joint injury results in a modest reduction to spontaneous activity. (A)
Representative open field centroid traces of CTRL and INJ mice. (B-D) Following INJ mice showed a
transient trend of decreased distance traveled and corresponding alterations to average speed and
percent time stationary in each 30 min recording. Mean±SEM, repeated measures two-way ANOVA.

Several gait parameters were transiently altered with joint injury. Duty factor (Fig.
2.7A), stride length, and stance width were linear related to animal velocity, therefore,
residuals were used for the analysis of these data. Due to inconsistent gait patterns (e.g.
hopping and non-weight bearing) 2 days following joint injury, animals of the INJ group
could not undergo digitization using AGATHA software. One week following joint injury
animals in the INJ group had a reduced ipsilateral hindpaw duty factor residual and a
corresponding increased duty factor residual for their contralateral hindpaw (Fig. 2.7B,C).
This imbalance between hindpaws was sustained until day 14 post-injury (Fig. 2.7D).
Forepaw duty factors were not influenced by hindpaw injury (Fig. 2.7E,F). There were
also no observed differences in animal walking speed between groups following joint
injury (Fig. 2.7G). Spatial symmetry, which highlights unilateral imbalances in the
step:stride length ratio, was altered one week following injury in hindpaws only (Fig.
2.7H,I). No differences were observed in fore or hindlimb measures of stance width or
bilateral measures of step length (data not shown).
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Figure 2.7: Non-invasive joint injury alters spatiotemporal gait parameters. (A) Duty factor is
dependent on velocity, concentric squares highlight reduced ipsilateral hindlimb duty factor 7 days post
INJ. (B and C) Individual hindlimb duty factor residuals (C=contralateral) and hindlimb duty factor
imbalance (D) were transiently altered following injury. (E and F) Forelimb duty factors and animal
velocity (G) were not altered by joint injury. Hindlimb gait became spatially asymmetric (H), no spatial
alterations to gait were observed in the forelimbs (I). Repeated measures two-way ANOVA w/
Bonferroni’s post-hoc; *=p<0.05, **=p<0.01, ****=p<0.0001.
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2.3.4 Joint injury leads to histological development of PTOA
Grading of articular cartilage revealed significant damage to select joint regions
following joint injury. Knee joints from animals of the INJ group showed evidence of severe
articular degeneration in the medial compartment of the joint compared to knee joints from
the CTRL group (Fig. 2.8A,B); median OARSI scores in MFC were 0.5 and 6 in CTRL
and INJ joints respectively (p<0.001), median scores within the MTP were 1.75 in CTRL
and 6 in INJ joints (p<0.01). In several cases, complete loss of cartilage on the MFC and
MTP was observed at the terminal timepoint. The LFC and LTP of animals in the INJ
group had median OARSI grades of 3 and 1.5, respectively, compared to median scores
of 0.5 and 1 in CTRL joints. Qualitatively, knee joints of the INJ group showed signs of
inflammation, fibrosis, synovial hyperplasia, and osteophyte formation when compared to
joints from the CTRL group.

Figure 2.8. Long-term degenerative changes to articular cartilage following injury. (A)
Representative histology shows full thickness articular defects in injured knee joints 113 days following
injury (B) INJ knees had elevated OARSI scores in the medial femoral condyle (MFC) and medial tibial
plateau (MTP), scale bar = 500 µm. LFC=lateral femoral condyle, LTP=lateral tibial plateau. Repeated
measures two-way ANOVA w/ Bonferroni’s post-hoc; **=p<0.01, ***=p<0.001.
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2.4 Discussion
In this work, we showed non-invasive knee joint injury in mice led to both transient
and long-term pain-related sensitivity and behavior changes consistent with those seen
in humans following acute traumatic joint injury28. Specifically, injury induced NF-κB
activation within the knee joint was associated with the onset of pain-related sensitivity,
gait alterations, weight bearing imbalances, and cartilage degeneration. Together these
data provide novel insight into the temporal progression of symptomatic disease within
this non-invasive murine model of PTOA.
We and others have previously shown injection models of inflammatory arthritis
result in transient changes to peripheral sensitivity following joint injury 63,93,220. Similarly,
surgical destabilization models of PTOA consistently result in hindpaw allodynia when
compared to sham operated animals; however, the onset, presentation, and duration of
this mechanical allodynia is varied and different from that observed in this non-surgical
PTOA model103,109,113,230. For example, Temp and colleagues showed mice experience a
biphasic pain-sensitivity phenotype following medial meniscus transection 113. Specifically,
acute allodynia primarily attributed to surgery resolved within one week and a second
onset of allodynia was observed four weeks after surgery. Withdrawal thresholds within
this second pain-sensitivity phase were of similar magnitude to those observed within the
one week post-surgery window. These results are in contrast to those reported within this
study; following non-invasive injury we observed sustained allodynia for two weeks. At
later timepoints withdrawal thresholds remained slightly lower in INJ ipsilateral hindpaws,
however, these thresholds were never as low as those observed in the two week postinjury period. Recent work by Heegde and colleagues corroborates the findings of the
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current study and shows that mechanically-induced joint injury is associated with a
transient and early onset of hindpaw allodynia124.
In addition to the development of chronic allodynia, we report a transient decrease
in the mechanical threshold to noxious stimuli at the injured knee joint. This acute
unilateral alteration is contrary to the chronic mechanical hyperalgesia observed following
surgically induced destabilization of the medial meniscus 218. The mechanisms that
contribute to these pain-related sensitivity alterations in differing models of PTOA remain
unknown. Further scientific inquiry should aim to shed light on the phenotypic changes to
sensory neurons that innervate structures within the injured knee joint; these studies may
better delineate the mechanistic differences in pain-sensitivity between PTOA
models105,231. In this study no bilateral sensitivity alterations were observed following
injury. This may suggest a lack of bilateral changes to the peripheral and central nervous
system following mechanically induced joint injury. This is in contrast to observations
made in injection models of inflammatory arthritis which have shown increased bilateral
expression of neuropeptides such as substance P and calcitonin gene related peptide in
the dorsal root ganglia and dorsal horn of the spinal cord shortly following injury 232,233.
These changes have been reported to be influenced by commissural spinal interneuron
crosstalk and increased systemic levels of pro-inflammatory cytokines234. To date, there
have been no reports of increased systemic pro-inflammatory cytokines within this noninvasive model of PTOA.
A novel finding of this study highlighted the early changes to non-evoked behaviors
of activity in gait/ambulation and weight bearing imbalance in stance. Prior studies have
not characterized the temporal progression of such behavioral changes following non36

invasive joint injury109,110,126. Anderson and colleagues showed slight alterations (6%
reduction in duty factor for ipsilateral hindpaws and corresponding, but non-significant,
7.3% increase in duty factor for the contralateral hindpaw) to gait parameters 1 day
following non-invasive joint injury126. In this study, we were unable to characterize
changes shortly following joint injury due to severe gait abnormalities including limb
disuse. Despite this, gait alterations one week post-injury appeared to be larger, with a
14.7% reduction in ipsilateral hindpaw and 9.9% increase in contralateral hindpaw duty
factor, respectively. Furthermore, alterations were sustained for two weeks (-3.9% and
+3.5% for ipsilateral and contralateral hindpaws, respectively) following joint injury. This
may suggest that the temporal progression of factors influencing behavioral alterations
are only just beginning 1 day following injury and more severe behavioral
phenotypes/abnormalities are present at slightly later timepoints within one week of knee
joint injury. Additionally, this study utilized a freely selected gait assessment as opposed
to the forced treadmill running assessment used by Anderson and colleagues which may
further explain these observed differences. Others have shown similar transient
alterations

to

gait

following

chemically,

genetically,

and

surgically

induced

arthritis109,110,230,235,236.
By 3 weeks following joint injury CTRL and INJ groups appear to be similar in most
behavioral measures assessed in this study. This is despite persistent alterations to joint
morphology and mechanics (e.g. development of osteophytes, cartilage lesions, synovial
hyperplasia, reduced range of motion)29–31,68,211. With that said, these findings point to
consistent changes in behavior under conditions that minimize animal fatigue and
external stresses. Mice are widely believed to temporarily mask pain-related behaviors
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during periods of prompted stimulation or stress such that activity changes associated
with freely selected behaviors may be of particular value to understanding symptomatic
joint pathology in murine models122. Future studies might benefit from assessments that
allow for quantification of freely selected behaviors including animal rearing, running
wheel use, and place preference122,237. With this in mind, a careful understanding and
pairing of complementary behavioral tests that assess different aspects of pain-related
sensitivity in disease are important for accurate and consistent characterization of
symptomatic profiles in animal models of PTOA.
In vivo bioluminescent imaging enabled longitudinal quantification of bulk NF-κB
pathway activation following knee joint injury. Data suggested that early NF-κB signaling
was correlated (Appendix A, Fig A.3) with the acute and chronic presentation of hindpaw
allodynia. Early increases in NF-κB-driven luminescence were also associated with more
severe cartilage erosion at the terminal timepoint (Appendix A, Fig. A.4). These data
suggest acute NF-κB signaling following injury may be predictive of the symptomatic and
structural progression of PTOA. The week long elevation in NF-κB-driven luminescence
observed in this study is in contrast to changes observed following surgically induced
knee joint injury. In studies using surgically induced PTOA models, joint injury has been
shown to elicit a prolonged elevation in NF-κB-driven luminescence for up to 6
weeks118,238. This suggests the systemic effects of surgery, with consequences for the
prolonged elevation of inflammatory mediators, may elicit sustained alterations in joint
inflammation and associated pain-related sensitivity in these widely utilized surgical
models of PTOA. It is therefore imperative to consider these factors when comparing
outcomes across differing pre-clinical animal models of PTOA.
38

In conclusion, the non-invasive model of PTOA described in this study may be
valuable for studying the early pathological changes following acute traumatic joint injury
and how they relate to pain-related sensitivity and behavioral changes without the
confounding nature of a surgical incision. Nevertheless, further work to better dissect the
temporal development and presentation of pain and sensitivity alterations in PTOA should
be performed to help direct future treatment strategies that may prevent both the
histological and painful progression of disease.
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Chapter 3
Intra-articular delivery of an NF-κB inhibitor in a noninvasive loading model of post-traumatic
osteoarthritis
3.1 Introduction
In Chapter 2 we showed that acute NF-κB activation within the knee joint was
coincident with increased mechanical sensitivity at the hindpaw. Additionally, we showed
that transient activation of NF-κB was associated with the development of several other
evoked and non-evoked behavioral changes that were not observed following sham
loading within the control (CTRL) group. Longitudinal in vivo imaging of NF-κB activation,
as described in Chapter 2, allowed us to determine an appropriate window for therapeutic
intervention following joint injury. In this chapter, we sought to inhibit NF-κB signaling in
the knee joint following injury via various local delivery strategies.
Increased NF-κB activity has been implicated in the development of pain following
peripheral injury and recent data suggest NF-κB may be directly responsible for
sensitization in some pain-related ion channels213–215. Furthermore, human studies have
shown that patients with worsening symptomatic OA have increased mRNA and protein
level expression of p-65, MMPs, and IL-1β within the knee joint239. NF-κB activation via
inflammatory mediators has also been shown to play a causal role in the increased
production of neurotrophic factors such as nerve growth factor (NGF) 240. Indeed, these
neurotrophic factors are known to induce further context dependent NF-κB signaling and
play a pivotal role in injury induced sensitization 241,242. Additionally, these factors have
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been observed at high concentrations in synovium and cartilage following joint injury 58,243–
251.

While aberrant NF-κB signaling is thought to drive the excessive production of pro-

algesic factors in symptomatic OA, many studies have sought to elucidate the role of
these pro-algesic molecules independently of NF-κB252–254. While these approaches have
shown analgesic benefits in arthritic patients adaptation of therapies, such as tanuzamib,
beyond clinical trials has been limited due to long-term deleterious effects on cartilage
and bone252,255,256. Therefore, strategies that target pain and inflammatory signaling
pathways via alternative mechanisms are of interest in the disease-modifying treatment
of symptomatic OA.
Given the role of NF-κB activation in the development of OA, it has been identified
as a promising druggable target for the treatment of disease. Pre-clinical studies have
shown protective effects of selective IκB kinase 2 (IKK-2) inhibitors, such as 8-(5-Chloro2-(4-methylpiperazin-1-yl)isonicotinamido)-1-(4-fluorophenyl)-4,5-dihydro-1Hbenzo[g]indazole-3-carboxamide (PHA-408) (Fig. 3.1), highlighting their potential as
disease-modifying OA drugs76,77. Specifically, PHA-408, a low molecular weight (560 Da),
highly selective inhibitor of IKK-2, has been shown to prevent the development of
inflammatory arthritis in streptococcal cell wall and lipopolysaccharide preclinical animal
models76. Furthermore, direct inhibition of the NF- κB signaling pathway has been shown
to have analgesic benefits following inflammatory injuries 66,257–259. However, off-target
effects upon systemic delivery and rapid clearance of small molecules from the joint
following intra-articular delivery have limited their therapeutic effect 51,260. The proven
efficacy of IKK-2 inhibitors when administered systemically motivates the development of
sustained release intra-articular delivery strategies for the treatment of OA. These
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Figure 3.1: NF-κB canonical signaling and PHA-408. The canonical NF-κB pathway can be activated
by many protein-receptor interactions which ultimately leads to phosphorylation of IKKβ/IKK-2 and
subsequent phosphorylation of the endogenous super-repressor of NF-κB, IκBa. The now heterodimeric
p65/p50 complex can translocate to the nucleus, binds its consensus sequence(s), and upregulate
transcription of pro-inflammatory as well self-regulatory gene sets. PHA-408 selectively inhibits IKK-2
phosphorylation and thus prevents downstream pathway activation.

strategies may help to reduce the deleterious effects of repeated systemic administration
and prolong drug residence times within the joint.
Sustained release drug depots have shown promise in clinical translation for the
treatment of OA175,261. Poly(lactic-co-glycolic) (PLGA), is FDA approved, and has long
been utilized as a polymeric drug carrier for its tunable sustained drug release
characteristics; however, acidic breakdown products from the polymer are known to lead
to inflammation. Amphiphilic block polymers combining polyethylene glycol (PEG) and
PLGA can efficiently encapsulate small hydrophobic drug molecules for sustained
release. These block polymers also have reduced inflammatory effects due to the
incorporation of PEG which serves to mask the inner PLGA core 180. Prior work has shown
that PEG-PLGA microparticles can remain entrapped in the synovial cavity for up to 4
weeks following intra-articular injection 179. Similarly, silk fibroin (SF) microparticles have
been shown to improve joint residence times of locally injected drugs by nearly 4-fold
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when compared to non-particle formulations184. SF also exhibits limited immunogenicity,
tunable temporal bioresorbable characteristics, and the potential for sustained release of
low molecular weight hydrophobic drugs183,262.
In Chapter 3, work aimed to investigate the disease-modifying potential and
biodistribution of locally delivered PHA-408 following non-invasive mechanical joint injury.
Additionally, we formulated and explored the efficacy of PEG-PLGA and SF
microparticles for the sustained release of PHA-408 to determine if a single intra-articular
dose of a sustained release preparation may influence the development of symptomatic
PTOA.

3.2 Methods
3.2.1 Joint injury and drug delivery
All procedures were performed with approval of the Washington University
Institutional

Animal

Care

and

Use

Committee.

Transgenic

FVB.Cg-Tg(HIV-

EGFP,luc)8Tsb/J mice (male, 9-12 weeks of age) were used in the four animal cohorts
described in this chapter.
A preliminary study was used to determine intra-articular PHA-408 dosing. In this
work, mice received a single intra-articular injection of mono-iodoacetate (0.1 mg/5 µL,
MIA) and two subsequent intra-articular injections of PHA-408 (0.1 µg/ 5 µL, n=4) or
vehicle (saline+0.1% DMSO, n=3) at 0 and 48 h following MIA injection. Drug treatment
had minimal impact on joint localized NF-κB signaling (Fig. 3.2A). However, early delivery
of PHA-408 reduced hindpaw allodynia (Appendix B, Fig. B.1) and appeared to have
modest protective effects on articular cartilage one month following MIA injection (Fig.
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Figure 3.2: Preliminary data suggested intra-articular administration of PHA-408 protects against
cartilage degeneration in an inflammatory model of arthritis. Following administration of monoiodoacetate (0.1 mg, MIA) mice received vehicle (Veh) or PHA-408 (0.1 µg, Tx) injections (0 and 48 h
post-MIA injection). (A) Tx knees showed minimal alteration to NF-κB-driven luminescence when
compared to Veh injected knee joints. (B) Veh treated joints showed loss of Safranin-O staining in the
lateral tibial plateau (arrowhead) whereas Tx (C) joints did not 4 weeks following MIA injection. Scale
bar = 500 µm. Repeated measures two-way ANOVA.

3.2B,C). Based on these data, PHA-408 dosing was increased in hopes of reducing
localized NF-κB-driven luminescence66.
To first determine the efficacy of local NF-κB inhibition following mechanical joint
injury, mice were randomly assigned to naive (CTRL, n=4), joint injury (INJ, n=6), or joint
injury plus treatment (INJ/Tx, n=5) groups. Following joint injury, as described in Chapter
2, mice received a single intra-articular injection of PHA-408 (3 µg/5 µL, sterile saline +
0.1% DMSO, Alchem Pharmtech Inc, Monmouth Junction, NJ) or vehicle (sterile saline +
0.1% DMSO) and were sacrificed 48 h post-injury (Fig. 3.3) to study the immediate cellular
effects of joint injury and drug treatment on articular cartilage (described in Section 3.2.6).
A separate cohort of mice was used to test for drug related effects using
longitudinal measures described in Chapter 2. Mice from cohort 1 (Chapter 2) were
randomly assigned to joint injury plus treatment (INJ/Tx, n=5). Animals in the INJ/Tx group
received two intra-articular injections of PHA-408 (3 µg/5 µL), one immediately following
injury and another 48 h post-injury.
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Figure 3.3: Study timeline. Behavioral assessments and timepoints mimic those described in Chapter
2. Mice in INJ/Tx group received two intra-articular injections (5 min and 48 h) following joint injury, mice
in the INJ/TxMP group only received one intra-articular injection 5 min following joint injury. Mice used
for in situ live-dead imaging were sacrificed (*) 48 h following joint injury and received only one intraarticular injection. Mice used for biodistribution and clearance studies were sacrificed (*) 30 min, 2, 72,
or 168 h following joint injury.

To test the effect of a sustained release drug formulation, mice in cohort 3 received
a single intra-articular injection of PHA-408 loaded PEG-PLGA microparticles (INJ/TxMP,
3 µg/5 µL; synthesis described in Section 3.2.3), PHA-408 (1 µg/5 µL), or vehicle (in vivo
imaging n=2-5 group/timepoint; hindpaw sensitivity n=2 group/timepoints) and were
tracked for 1 week to assess changes in NF-κB-driven luminescence and hindpaw
sensitivity. Finally, to test the biodistribution and clearance behaviors PHA-408 (described
in Section 3.2.7), mice in cohort 4 received two intra-articular injections of PHA-408 (3
µg/5 uL) or vehicle (0 and 48 h) following knee joint injury (n=2-5 per group/timepoint).

3.2.2 Gene expression
Gene expression was assayed using qPCR on an Applied Biosystems TM
StepOnePlusTM Real-Time PCR System (Software v2.3, Foster City, CA). Briefly,
immortalized human synovial sarcoma cells (SW982, ATCC, Manassas, VA) were
seeded (300,000 cells/well) on a 6-well plate and allowed to grow until 90% confluency
(37°C, 5% CO2). Cells were then co-treated with recombinant human interleukin-1 beta
(1 ng/mL; IL-1β, R&D Biosystems, Minneapolis, MN) and PHA-408 (0.1 to 10 µM).
Following a 6 h incubation period, cells were lysed using RLT buffer (Qiagen, Hilden,
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DEU) + 1% mercaptoethanol. RNA isolation was performed using the QIAGEN TM Mini kit
(Qiagen). Briefly, samples were homogenized using a QIAshredderTM column and RNA
was then bound to an RNeasy spin column. The sample was then washed, and DNA was
digested using DNAse I. RNA was eluted with RNAse-free water and RNA concentration
and purity were determined using the 260/280 ratio in a NanoDrop™ system
(ThermoFisher, Waltham, MA). RT-PCR was performed using the iScript cDNA Synthesis
Kit (BioRad, Hercules, CA). qPCR was used to detect amplification of tumor necrosis
factor alpha (TNF-α), interleukin-6 (IL-6), and interleukin-8 (IL-8) (Applied Biosystems,
Foster City, CA) using ΔΔCt; GAPDH and ACTB were used as housekeeping genes and
data were normalized to untreated controls.

3.2.3 PEG-PLGA microparticle formulation
PEG-PLGA microparticles were fabricated using a coaxial microfluidic phase
separation method by Dr. Era Jain263. A 2% w/v PEG-b-PLGA (PEG 2kDa, PLGA
11.5kDa, Sigma-Aldrich, St. Louis, MO) solution prepared in dichloromethane (DCM) was
flowed through an inner needle (31 G) at 0.2 mL/h and a 5% w/v polyvinylalcohol (PVA)
solution was passed through an outer concentric needle (16 G). PEG-PLGA droplets were
collected in a TeflonTM bath in 5% w/v PVA under constant stirring. Following washing
and sieving (70 μm nylon filter) microparticles were vacuum dried and stored. Drug loaded
microparticles were prepared by adding PHA-408 to the DCM/PEG-PLGA (1:10
drug:polymer ratio) phase prior to microparticle preparation. Microparticles were imaged
and their average diameter was calculated by measuring ≥100 microparticles per
experimental run using ImageJTM (National Institutes of Health, Bethesda, MD).
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3.2.4 Silk fibroin microparticle formulation
Silk fibroin (SF) solution was prepared as previously described 181,264. Briefly, whole
silk cocoons were cut into dime sized pieces and boiled in 0.025M sodium bicarbonate
for 30, 60, or 120 min for sericin residue removal. Silk was then washed (20 min, 3X,
diH2O) and allowed to dry overnight. Dried silk was solubilized in 9.3M lithium bromide
(4h, 60°C) at a 20% w/v ratio. The solution was transferred into a dialysis cassette
(MWCO 3500, Thermo Scientific) and dialyzed against 5 L of diH20 for 48 h with constant
stirring, water was exchanged every 12 h. Dialysate was then removed and centrifuged
(Sorvall Evolution RC, Thermo Fisher) at 12,700 RCF (20 min, 4°C) to remove aggregates
and debris. The solution was diluted to a final 6% (w/v) solution with diH2O and stored at
4°C.
SF microparticles were prepared by mixing 3 mL extracted SF (30, 60 or 120 min)
with 12 mL of 5% PVA (1:4 silk:PVA ratio) and casting the mixture in a polystyrene petri
dish (100 mm) to form a film. The film was re-suspended in diH2O and microparticles
were washed, centrifuged, and lyophilized. PHA-408 loading was performed post
microparticle synthesis by mixing PHA-408 in ethanol (EtOH, 2 mg/mL) with
microparticles (1:10 drug:microparticle ratio) for 3 days under constant stirring. EtOH was
then allowed to evaporate, microparticles were subsequently washed with EtOH,
lyophilized, and stored at 4°C. Microparticle synthesis was performed by Dr. Burcin Yavuz
at Tufts University.

3.2.5 In vitro release and drug bioactivity
For quantification of drug release via high performance liquid chromatography
(HPLC) 10 mg of PHA-408 loaded microparticles were incubated with 1 mL of phosphate
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buffered saline (PBS), pH 7.4 at 37°C. At regular time intervals PBS was collected and
an equivalent volume of fresh PBS was added. Samples were stored at -80°C for later
analysis. Collected aliquots were analyzed via HPLC (Agilent 1200 system, Agilent
Technologies, Santa Clara, CA) to measure released PHA-408. HPLC analyses were
performed by Dr. Burcin Yavuz at Tufts University. Following extraction in dimethyl
sulfoxide (DMSO) samples were run through an Agilent Poroshell 120 EC-C18 column
(2.7 μm, 4.6mm×50mm, Agilent Technologies) at 25°C. A mobile phase of
methanol:water with 0.1% trifluoroacetic acid (60:40) was used at a flow rate of 0.75
mL/min and UV absorption was measured at 260 nm. Drug concentration in aliquots was
determined by comparison to a standard curve.
To determine drug bioactivity following release from microparticles, PHA-408
loaded microparticles (10 mg/mL) were suspended in Dulbecco’s Modified Eagle Medium
(DMEM), supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin, and
placed in a TranswellTM insert at 37°C. At regular time intervals, aliquots of media
incubated with PHA-408 loaded microparticles were collected and an equivalent volume
of fresh media was added to each TranswellTM. NF-κB inhibition from released PHA-408
in microparticle incubated media was measured using a SW982 reporter cell line
transduced with lentivirus carrying an NF-κB luciferase response element construct
(pHAGE

NFκB-TA-LUC-UBC-GFP-W,

Addgene,

Watertown,

MA) 265.

Following

transduction (1 µL, 4.3 multiplicity of infection), cells were plated and allowed to attach.
Media was then supplemented with 1 ng/mL of recombinant human interleukin-1 beta (IL1β, R&D Biosystems, Minneapolis, MN) to induce an inflammatory response as measured
by increased luciferase expression in the transduced cells. Some wells received dosing
48

with an aliquot of media incubated with PHA-408 loaded microparticles as described
above, and the luminescence signal was measured following a 24 h incubation period
(Enspire, PerkinElmer) using Bright-GloTM (Promega, Madison, WI). Bioluminescence
values were normalized to IL-1β only treated controls.

3.2.6 In situ live-dead cellular imaging
Intact femurs from animals in cohort 2 were harvested 48 h following joint injury for
in situ live-dead imaging (Fig. 3.4A-C). Knees were grossly dissected from mice by cutting
through the mid-femoral diaphysis. Muscle and connective tissue were then removed
from the around the knee joint, patellar tendon and medial/lateral collateral ligaments
were transected, and the knee joint was disarticulated via tensile overload. Care was
taken to avoid any contact with articular cartilage and samples were continuously irrigated
with hypertonic (400 mOsm) media during dissection 266,267. Jeweler forceps were used to
remove medial and lateral menisci as well as posterior/anterior cruciate ligament

Figure 3.4: In situ live-dead imaging setup. Following staining, intact femurs where placed atop a
#1.5 coverslip and fixed in custom holder (A) such that the femoral shaft was positioned at a ~30° angle
with respect to the x-axis and both condyles made complete contact with the coverslip as shown from
the sagittal plane. (B) Representative coronal histology section and (C) corresponding max intensity
projections (100µm z-stack) of fluorescence images show cell nuclei in the articular cartilage of both the
lateral (left) and medial (right) femoral condyles (LFC/MFC) in the transverse imaging plane, scale bar
= 200 µm.
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remnants. Cleaned femurs were stained with Hoechst 33342 (10 µM, ThermoFisher),
Calcein-AM (5 µM, Invitrogen, Carlsbad, CA), and Propidium Iodide (PI, 5 µM,
ThermoFisher) for 1 h at 37°C34,43,268. Following staining, intact femurs were imaged
(FV1200, Olympus, Tokyo, JPN). Z-stacks (100 µm thickness) were acquired of each
femoral condyle. Hoechst+ and PI+ cell number per condyle was determined via an
automated thresholding-based ImageJ script.

3.2.7 Biodistribution of PHA-408 following intra-articular injection
Mice (n=2-5 per group/timepoint) in cohort 4 underwent compressive joint injury
followed by intra-articular injections of either PHA-408 (3 µg/5 µL) or vehicle (5 µL)
immediately following and 48 h post-injury. At terminal timepoints (30 min, 2 h, 3 d, 7 d)
1 mL of blood was collected by cardiac puncture and serum was obtained following
centrifugation. Lymph nodes (inguinal and lumbar), knees, and urine were collected at
the time of sacrifice269,270. Lymph nodes were suspended in 500 µL acetonitrile (ACN),
and homogenized (Mini-BeadBeaterTM, BioSpec, Bartlesville, OK). Knees were flash
frozen in liquid nitrogen, homogenized (BioPulverizerTM, BioSpec), and suspended in 2
mL of ACN. Samples were then vortexed for 2 h and centrifuged to collect clarified ACN.
Drug concentrations in serum, urine, lymph nodes, and knee tissue were estimated via
LC-MS upon an Agilent 1200 series HPLC instrument and an Agilent 6410 triplequadruple mass spectrometer operated in positive electrospray ionization mode (collision
gas flow rate: 11 L/min, source block temperature: 300°C). Samples (20 µL) were injected
into a C18 column (4.6×100 mm, 3.5 μm, Agilent) at 37°C using a gradient elution method
(Water and ACN mix) at a flow rate of 0.65 mL/min. PHA-408 was quantified by multiple
reaction monitoring (Q1/Q3, 560.246/514.113) with a 51V collision energy. LC-MS
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analyses on ACN extracted tissues were performed by Dr. Burcin Yavuz at Tufts
University. High levels of background signal were detected in lymph nodes of vehicle
injected mice, thus a noise floor was defined for lymph node tissues (mean+2*SD, vehicle
injected mice).

3.2.8 In vivo luminescence imaging of NF-κB activity
To assess local NF-κB activation following joint injury, in vivo bioluminescent
imaging was performed as described in Chapter 2, Section 2.2.2.

3.2.9 Pain-related hindpaw sensitivity
The effects of local NF-κB inhibition on the development of mechanical allodynia
following joint injury were using von Frey filaments as described in Chapter 2, Section
2.2.3.

3.2.10 Pain-related hyperalgesia
The threshold for contact hyperalgesia was tested at the knee joint using a small
animal algometer as described in Chapter 2, Section 2.2.4.

3.2.11 Hindpaw thermal sensitivity
Hindpaw thermal sensitivity to hot and cold stimuli were tested using methods
previously described in Chapter 2, Section 2.2.5.

3.2.12 Static weight bearing
Alterations to static weight bearing were assessed using methods described in
Chapter 2, Section 2.2.6.
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3.2.13 Spontaneous activity
Freely selected activity during the animal dark cycle was tracked as previously
described in Chapter 2, Section 2.2.7.

3.2.14 Histology
Following sacrifice (113 days post-injury), ipsilateral knees were collected for
histology and processed as described in Chapter 2, Section 2.2.9. Stained sections were
graded to consensus by two blinded graders using OARSI scoring 227.

3.2.15 Statistical analysis
Statistical analyses were performed using GraphPad Prism 8.0 (GraphPad
Software, La Jolla, CA). A one-way ANOVA with Dunnett’s post-hoc was performed to
test for differences in ΔΔCt values in SW982 cells, all comparisons were made to IL-1β
only treated controls. A repeated measures two-way ANOVA with Bonferroni’s post-hoc
was used to test for differences in Hoechst+ and PI+ cell counts between CTRL, INJ, and
INJ/Tx femoral condyles. A repeated measures two-way ANOVA with Bonferroni’s posthoc was used to test for differences between INJ and INJ/Tx groups at each timepoint for
all longitudinal measures. In vivo imaging and 50% withdrawal threshold data were logtransformed (base 10) to better meet ANOVA assumptions. A repeated measures twoway ANOVA with Bonferroni’s post-hoc was used to test for differences in cartilage
OARSI scores at each cartilage site between INJ and INJ/Tx groups. Statistical
significance was set at p < 0.05.
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3.3 Results
3.3.1 PHA-408 effectively reduced IL-1β induced inflammatory
signaling in vitro
The small molecule inhibitor of IKK-2, PHA-408, reduced inflammatory signaling
following co-stimulation with IL-1β in vitro. Shortly after stimulation with the inflammatory
mediator IL-1β, PHA-408 treated cells showed a reduction in transcriptional levels of the
inflammatory and immunomodulatory genes TNF-α, IL-6, and IL-8 (Fig. 3.5A-C).

Figure 3.5: Micromolar concentrations of PHA-408 effectively reduce IL-1β induced inflammatory
signaling in vitro. PHA-408 treated cells showed reduced mRNA level of TNF-α (A), IL-6 (B), and IL-8 (C)
when compared to non-drug treated IL-1β stimulated cells. One-way ANOVA with Dunnett’s post-hoc;
*=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001.

3.3.2 Characterization of an NF-κB reporter cell line
Transduced SW982 cells expressed GFP in a viral titer dependent manner (Fig.
3.6A). Furthermore, transduction was stable following multiple passages (Fig. 3.6B) and
IL-1β stimulated NF-κB-driven luminescence showed a dose (Fig. 3.6C) and time
(Appendix B, Fig. B.2) dependent decrease with PHA-408 mediated NF-κB inhibition.

53

Figure 3.6: Characterization of NF-κB luciferase reporter cell line. SW982 cells were transduced
with an NF-κB responsive lentivirus at varying viral concentrations. (A) Increasing viral concentration
led to increased levels of GFP+ cells when assessed via fluorescence microscopy (top) and flow
cytometry (bottom). (B) Cells remained stably transduced with passaging (1 µL virus, green box
represents mean±SD at P0). (C) NF-κB-driven luminescent shows a dose dependent response with
increasing PHA-408 concentration when co-stimulated with IL-1β (1 µL virus, 4.3 MOI).

3.3.3 Local delivery of PHA-408 exhibits chondroprotective effects
shortly following joint injury
Shortly following joint injury an increase in PI staining was observed in fluorescent
images of the MFC (Fig. 3.7A). Cell numbers in the mid-contact region of femoral condyle
articular cartilage, as assessed by Hoechst+ staining, were not different between groups
(Fig. 3.7B). Injured knee joints had an increased number of PI + cells within the MFC when
compared to CTRL; however, PI+ cells were reduced in INJ/Tx MFCs when compared to
untreated INJ MFCs (Fig. 3.7C).
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Figure 3.7: Short-term chondroprotective effect of PHA-408 following loading. (A) Representative
maximum intensity projected images of the medial femoral condyle (MFC) from each group. (B) No
differences in lateral femoral condyle (LFC) or MFC cell number were observed 48 h post joint injury.
(C) INJ led to an increase in PI+ cells in the MFC, however, INJ/Tx MFC PI+ cell count was reduced
when compared to INJ only. Scale bar = 100 µm, compass rose: L=lateral, A=anterior, M=medial,
P=posterior. Repeated measures two-way ANOVA w/ Bonferroni’s post-hoc; **=p<0.01, ****=p<0.0001
vs CTRL; #=p<0.05 INJ vs INJ/Tx.
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3.3.4 Characterization of PEG-PLGA and SF microparticles and in
vitro drug release
PEG-PLGA microparticles had an average diameter of 11.9±7.6 µm (Fig. 3.8A,C)
and a 37% drug loading efficiency (final drug loading ratio 1:27, drug:microparticle). PEGPLGA microparticles exhibited sustained release characteristics with limited burst release
in vitro, their estimated drug release half-life was 19.7±3.2 days (Fig. 3.8D). Furthermore,
100% of loaded drug was eventually released from PEG-PLGA microparticles into PBS
release buffer as particles degraded.
SF microparticles had an average diameter of 13.4±7.1 µm (Fig. 3.8B,C) and drug
loading efficiencies of greater than 99% across all formulations (final drug loading ratio
1:10, drug:microparticle). SF microparticles showed the potential for sustained release
for over two months in vitro; however, only ~10% of loaded PHA-408 was released from
SF microparticles into PBS release buffer in all formulations (Fig. 3.8D). The average SF
microparticle drug release half-life was 16.2±2.4 days.
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PHA-408 released from both PEG-PLGA and SF microparticles remained
bioactive and effectively inhibited IL-1β induced NF-κB signaling in a reporter cell line
(Fig. 3.8E). NF-κB inhibition from microparticle conditioned media was similar to inhibitory
levels observed with 10 µM concentration of free drug.

Figure 3.8: Characterization of PEG-PLGA and SF microparticles. Representative bright field (A)
and SEM (B) images of PEG-PLGA and SF microparticles, respectively. (C) Size distribution of PEGPLGA and SF drug loaded microparticles. All particle formulations showed continuous release of PHA408 for 80 days (D) and PHA-408 released from microparticles showed sustained inhibition of IL-1β
induced NF-κB activation in SW982 reporter cells (E), inhibition was near levels seen with 10 µM of free
drug. Scale bar = 100 µm.
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3.3.5 Local delivery of PHA-408 following joint injury has modest
effects on NF-κB activity and animal behavior
Locally delivery of PHA-408 following joint injury did not significantly alter the
transient rise of NF-κB-driven luminescence within injured knees; however, NF-κB activity
was elevated in INJ/Tx joints 14 days following knee joint injury when compared to INJ
untreated joints (Fig. 3.9A,B). The development of allodynia shortly following injury was
similar in INJ and INJ/Tx groups (Fig. 3.9C). Withdrawal thresholds in the INJ/Tx group

Figure 3.9: Intra-articular injection of PHA-408 follow joint injury has modest effects on NF-κB
activity and animal behavior following knee joint injury. (A and B) NF-κB activity in drug treated
joints was elevated two weeks following joint injury. INJ and INJ/Tx animals showed similar 50%
withdrawal (C) and escape (D) thresholds. (E) INJ/Tx mice had a more rapid recovery towards uniform
static weight bearing. Repeated measures two-way ANOVA w/ Bonferroni's post-hoc; ***=p<0.001,
****=p<0.0001.
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did show a trend towards recovery at later timepoints, however, these were not
significantly different from INJ 50% withdrawal thresholds (99/113 d, p=0.09, INJ v
INJ/Tx). INJ and INJ/Tx groups had similar thresholds to noxious mechanical stimuli at
the injured knee joint (Fig. 3.9D). Drug treatment improved static weight bearing in the
INJ/Tx group 8 days following injury when compared to the INJ, untreated, group (Fig.
3.9E).
Alterations to free ambulation following joint injury were similar in INJ and INJ/Tx
groups (Fig. 3.10A-C). On average, distance traveled in both groups remained below
baseline for 8 weeks following knee joint injury.

Figure 3.10: Treatment does not modify freely selected ambulation. (A) Animal matched centroid
traces at baseline and 2 days following knee joint injury. INJ/Tx animals had similar alterations to their
change in distance traveled (B) and percent time stationary (C) when compared the INJ group.
Mean±SEM, repeated measures two-way ANOVA w/ Bonferroni’s post-hoc.

No alterations to thermal sensitivity at the ipsilateral hindpaw were observed with
the presentation of a hot stimulus between INJ and INJ/Tx groups (Fig. 3.11A).
Interestingly, animals in the INJ group had reduced latencies to withdrawal from a cold
thermal stimulus, however, this was prior to knee joint injury and subsequent drug
treatment (Fig. 3.11B).
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Figure 3.11: Thermal sensitivity at the hindpaw with drug treatment. Latency to withdrawal from a
hot (A, 50°C) thermal stimulus was not found to be different between INJ and INJ/Tx at the ipsilateral
hindpaw. Latency to withdrawal from a cold (B, 0°C) thermal stimulus, however, was reduced at baseline
in the INJ group. Repeated measures two-way ANOVA w/ Bonferroni’s post-hoc; *=p<0.05.

3.3.6 Drug treatment does not improve long-term articular cartilage
outcomes
Drug treatment was not effective in modifying the long-term degeneration of
articular surfaces in the joint (Fig. 3.12A,B). Similar OARSI scores were observed in INJ
and INJ/Tx joints 16 weeks following knee joint injury (Fig. 3.12C). A trend of increased
degeneration in the medial joint compartment was consistent between groups.

Figure 3.12: Drug treatment does not influence long-term degenerative changes to articular
cartilage following injury. Representative histology of INJ (A) and INJ/Tx (B) knees. (C) OARSI scores
showed similar levels of degeneration to articular surfaces of INJ and INJ/Tx knee joints in both the
lateral and medial compartments of the joint 16 weeks following joint injury. Repeated measures twoway ANOVA w/ Bonferroni’s post-hoc.

3.3.7 PHA-408 is rapidly cleared from the knee joint following intraarticular administration
Due to the limited efficacy of locally delivered free PHA-408 following joint injury,
we hypothesized short joint residence times of the low molecular weight drug might be
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contributing to the observed outcomes. Following intra-articular injection, low molecular
weight drugs are rapidly cleared from the joint via the circulatory and lymphatic systems.
Despite suspension based PHA-408 injections (Appendix B, Fig. B.3), drug was rapidly
cleared from the joint space to draining lymph nodes (Fig. 3.13A). PHA-408 was detected
within injected knee joints for 72 h following the first intra-articular injection (Fig. 3.13B).
The estimated intra-articular half-life for PHA-408 was 41.2 min. Drug was not detected
in knee joints one-week post-injection. Drug levels above the lower detection limit
(Appendix B, Fig. B.4) persisted in contralateral, uninjected, limbs for 2 h following

Figure 3.13: Drug biodistribution and clearance. (A) Schematic highlighting tissues removed for
biodistribution and clearance assessments following intra-articular injection with PHA-408 (t=0 and 48
h). Drug was rapidly cleared from (B) knee tissue, as well as (C) inguinal and (D) lumbar lymph nodes,
(E) serum, and (F) urine following repeated intra-articular injections at t=0 h and t=48 h. Solid line=lower
limit of detection, dashed line=noise floor.
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injection. Average drug concentrations within injected limbs were 17.8 µM and 4.0 µM at
30 min and 2 h timepoints, respectively. Drug levels in major draining lymph nodes,
serum, and urine all exhibited a rapid reduction in drug concentration with time following
intra-articular injection (Fig. 3.13C-F).

3.3.8 Sustained release of PHA-408 does not overtly improve
measured outcomes over freely administered drug
Given the rapid clearance of suspension based PHA-408, we hypothesized local
delivery of sustained release PHA-408 loaded PEG-PLGA microparticles may elicit
protective effects against joint injury-induced NF-κB signaling and pain-related behavioral
changes shortly following injury. A trend of increased NF-κB-driven luminescence was
observed in knees of INJ/Veh, INJ/Tx, and INJ/TxMP treated groups as compared to
baseline (Fig. 3.14A). Trends in 50% withdrawal thresholds were similar in INJ/Veh,
INJ/Tx, and INJ/TxMP groups (Fig. 3.14B). Thus, treatment with free drug or a sustained
release preparation did not overtly resolve pain-related sensitivity or inhibit an increase in
NF-κB activity shortly following joint injury. Furthermore, a sustained release SF
microparticle formulation did not prolong drug residence time withing the knee joint
following intra-articular administration (Appendix B, Fig. B.5)

Figure 3.14: PEG-PLGA microparticles do not overtly improve early PTOA related outcomes.
One-time drug treatment in soluble or MP formulation did not alter the onset of NF-κB signaling in the
knee joint (A), or the development of allodynia (B) following knee joint injury.
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3.4 Discussion
Work in this chapter described the effects of locally delivered PHA-408 following
knee joint injury. Data suggested treatment with PHA-408 acutely protected chondrocytes
from injury initiated cell death. Despite these observed early effects on articular cartilage,
PHA-408 only modestly influenced the development of pain-sensitivity related behaviors
following knee joint injury. Furthermore, PHA-408 did not prevent the long-term
histological development of PTOA. Finally, we showed PHA-408 loaded PEG-PLGA and
SF microparticles provided sustained release of bioactive drug; however, local delivery of
drug-loaded

PEG-PLGA

and

SF

microparticles,

respectively,

did

not

alter

imaging/sensitivity outcomes or improve drug residence times within the joint following
injury. These results highlight the challenges of translating promising small molecule drug
candidates from in vitro development to animal models of disease.
Shortly following knee joint injury we observed increased chondrocyte membrane
permeability within the MFC of loaded knee joints. In comparison, changes within the LFC
were minimal. These early differences in medial/lateral chondrocyte health aligned with
histologic articular cartilage outcomes assessed 16 weeks following injury which showed
increased cartilage degeneration within the medial joint compartment. We hypothesize
acute delivery of PHA-408 following injurious loading may have reduced chondrocyte
necroapoptosis mediated cell death72,271–273. Indeed, others have shown similar
chondroprotective effects of NF-κB

inhibition

following

joint injury 67,68,77,164,274.

Nevertheless, these acute protective effects were inconsequential to long term joint
health. This may be in part due to the severity and chronic destabilizing nature of this
injury model35,43,70,275,276.
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Data described in Chapter 2, and prior work by Yan and colleagues, informed the
PHA-408 dosing strategy used in this chapter. Yan and colleagues showed cyclical
loading of the murine knee joint, albeit at a lower force amplitude of 6 N, led to robust
phosphorylation of p65 in chondrocytes within 12 h of loading, with additional P-p65
observed in synovium 48 h following knee joint injury68. In Chapter 2 we showed
longitudinal NF-κB-driven luminescent signal rapidly increased in a similar timeframe
following injurious loading. Signal peaked 3 days following knee joint injury and quickly
returned towards baseline by day 7, where it stayed for the remainder of the study. Given
these pathway kinetics, it seemed drug treatment immediately following injury may elicit
favorable disease-modifying outcomes. Indeed, Yan and colleagues further showed two
time (0 & 48 h post-injury) intra-articular administration of NF-κB inhibiting siRNA
nanoparticles following knee joint injury modestly reduced chondrocyte expression of Pp65, chondrocyte apoptosis, and cartilage lesion size; locally delivered siRNA also
entirely prevented the development of knee joint hyperalgesia68,69. As eluded to
previously, the contrasting results in observed outcomes between these studies may be
explained by the severity of loading induced knee joint injury. While 12 N cyclic loading
of the knee joint consistently leads to ligamentous rupture and subsequent joint
destabilization, 6 N loading has not been reported to induce such changes 29,121,207. These
significant and long-lasting changes to joint biomechanics following 12 N injury may
warrant an increase in drug dosing frequency and duration. To date, the long-term
efficacy of drug treatment following the 12 N injury model used in this study has remained
elusive142,277. However, preliminary dosing studies we performed in the MIA model of
arthritis suggested acute delivery of PHA-408 may protect articular cartilage from MIA
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induced changes. Together these data highlight the potential utility of infrequent/acute
NF-κB inhibition in the absence of a persistent destabilizing injury and suggest
alternative/additional dosing timepoints may be required following traumatic joint injuries
that chronically alter joint biomechanics77,164,278.
Given the chronic destabilizing nature of the injury model used in this study and
the observed clearance kinetics of free PHA-408 from the knee joint, we hypothesized a
sustained release drug depot might help to prolong intra-articular drug residence times
and improve measured outcomes described in this chapter. Large polymeric micron-sized
drug carriers have long been shown to have increased residence times when compared
to freely administered solutes168,172,173,184. Additionally, both PEG-PLGA and SF
microparticles have been used for the sustained release of various low molecular weight
hydrophobic drugs making them ideal carriers for the sustained release of PHA408179,183,279,280. Indeed, in vitro studies showed both microparticle formulations facilitated
the sustained release of PHA-408 and released drug showed effective inhibition of
inflammatory mediator induced NF-κB signaling. However, preliminary results following
the local delivery of drug loaded PEG-PLGA microparticles did not show an overt impact
on measured outcomes shortly following knee joint injury. Furthermore, drug levels within
the joint were below the lower detectable limit (1.99 nM) of our assay following local
delivery of drug loaded SF microparticles. This was despite a more than 15-fold increase
in total delivered/encapsulated drug. Given these factors, the long-term effects of PHA408 laden sustained release depots were not studied.
Acute treatment with PHA-408 led to increased NF-κB-driven luminescence in
INJ/Tx mice; although this result was somewhat surprising, similar observations have
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been previously reported following the administration of small molecule NF-κB inhibitors,
such as bortezomib and BAY 11-7082, in inflammatory disease states 82. Given this, the
acute effect of PHA-408 on NF-κB-driven luminescence was further explored in the
absence of knee joint injury. Results showed intra-articular delivery of PHA-408 or vehicle
control both led to slightly increased NF-κB-driven luminescence within injected knee
joints when compared to contralateral knees (Appendix B, Fig. B.6), however, these levels
were still far below those observed in INJ and INJ/Tx knees. The influence of high local
drug concentrations may elicit cytotoxic effects which is a further concern following intraarticular injection (Appendix B, Fig. B.7). Nevertheless, these results highlight an inability
to inhibit bulk knee joint NF-κB-driven luminescence following local administration of PHA408. Based on this, and the rapid rise and subsequent fall of NF-κB-driven luminescence
following injury, it seems possible NF-κB-driven luminescence at the whole joint level in
this reporter mouse line is not entirely representative of signaling kinetics within relevant
tissues such as articular cartilage and synovium. To this point Kobayashi and colleagues
have reported increased NF-κB activation in articular chondrocytes 8 weeks following a
knee joint destabilizing injury, this far exceeds the week long rise in signaling we observed
in this study67. Thus, NF-κB-driven luminescence in this mouse line may have limited
sensitivity in measuring injury and drug treatment induced changes to knee joint tissues
and is a limitation of this longitudinal study. Future cross-sectional studies, that rely on
histological outcomes rather than longitudinal in vivo imaging, may help to better dissect
the spatiotemporal activation of NF-κB in specific joint tissues post-injury 238. Indeed, in a
simplified ex vivo organ culture model, we observed effective inhibition of NF-κB signaling
with application of PHA-408 (Appendix B, Fig. B.8). In spite of the results reported in this
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dissertation, positive structural disease-modifying effects observed in less severe PTOA
models, such as the destabilization of the medial meniscus model, support the use of
local NF-κB inhibition for the treatment of PTOA 60,67,68,75,77,107,108,238,274,281.
In this study intra-articular administration of PHA-408 led to modest alterations in
pain-sensitivity related behaviors following knee joint injury. Interestingly, INJ/Tx mice
showed a trend towards increased 50% withdrawal thresholds in their ipsilateral hindpaw
at late timepoints within this study. This suggests acute treatment with PHA-408 following
knee joint injury may have had some long-term effect on pain-sensitivity even following
drug clearance from the joint. Others have shown similar peripheral sensitivity modulating
effects of anti-inflammatory drugs following traumatic joint injury; however, little work has
focused on the specific role of NF-κB inhibition in mediating pain-sensitivity related
behaviors in PTOA animal models69,109,111,218,282. Early delivery of NF-κB inhibitors has
been shown to impart similar long-lasting effects in inflammatory and neuropathic pain
models by modulating the local inflammatory environment at the site of injury and by
influencing the expression of nociception related proteins, such as the voltage gated
sodium channels NaV1.7 and NaV1.8, in tissue innervating sensory neurons (Appendix
B, Fig. B.9)64,214,257,283–286. Recent work has also highlighted the putative role P-p65 plays
in the direct gating of NaV1.7 activity in sensory neurons 215. These data suggest there is
a role for careful modulation of NF-κB in the treatment of painful inflammatory conditions
such as PTOA (Fig 3.15)58,215,295,287–294.
In general, the analgesic effects of disease-modifying OA drugs are poorly
understood. While many pre-clinical studies seek to characterize the structural influences
of drug treatment, they often overlook drug related impacts on pain-related behaviors 88.
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In some instances, however, the opposite has been true. For example, great promise had
been placed on the clinical development of tanezumab, a humanized monoclonal NGF
antibody, for the analgesic treatment of knee OA, however, its widespread adaptation has
been limited due to long-term deleterious effects on articular cartilage and bone
quality252,255,256. Indeed, subsequently conducted animal studies have shown tanezumab
may accelerate the onset of articular defects and osteophyte formation following joint
injury. Presumably, degenerative changes are accelerated due to increased joint loading
on the injured limb in the presence of the analgesic effects of tanezumab 296,297. With this
in mind, future work should simultaneously aim to better understand and treat both the
structural and symptomatic progression of OA.
In conclusion, the work described in this chapter showed the potential for PEGPLGA and SF microparticles to act as sustained release drug depots for the small
molecule NF-κB pathway inhibitor, PHA-408. Results also highlighted the short-term
chondroprotective effects of local PHA-408 delivery and the modest behavioral modifying

Figure 3.15: Traumatic joint injury triggers a pro-inflammatory/algesic cascade which
contributes to the symptomatic progression of PTOA. Following traumatic joint injury, local NF-κB
activation contributes to the increased production and release of pro-inflammatory/algesic/catabolic
molecules by the resident cells of the joint which contribute to erosive changes to joint structures.
Increased intra-articular levels of these factors may induce nerve fiber sprouting and sensitization, in
part, through NF-κB mediated signaling.
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impact repeated drug treatment had on longitudinal pain-sensitivity related behavioral
outcomes following joint injury. Drug treatment, however, did not influence the long-term
structural development of PTOA in injured knee joints. While this study ultimately failed
to show substantial long-term structural disease modification via local PHA-408 delivery,
the results still provide valuable insight into the temporal development of symptomatic
PTOA following knee joint injury. This work also highlights many of the hurdles which
must be overcome for successful small-molecule intra-articular drug delivery. Functional
assessments of pain-sensitivity related behaviors, such as those employed in this study,
should continue to be utilized to better understand what factors contribute to the
symptomatic progression of conditions such as OA. Hopefully, these approaches will help
to inform the future development of efficacious treatment strategies that slow or halt the
structural and symptomatic progression of musculoskeletal pathologies.
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Chapter 4
Electric field stimulation for the rapid functional
assessment of alterations to intact dorsal root
ganglion neuron excitability
4.1 Introduction
A diverse set of somatosensory neurons are required for physical perception.
Sensations of touch, temperature, taste, and pain are all transmitted via sensory neurons,
but the mechanisms by which these sensory stimuli are encoded and transmitted remain
unclear. For this reason, there is great need to further interrogate the neurophysiologic
basis of sensory neuron signaling. The functional assessment of cellular neurophysiology
has traditionally relied on manual patch clamp based techniques 191. While this approach
remains the gold standard for understanding the electrophysiological basis of ion channel
dynamics and action potential propagation, these methods are limiting due to their relative
technical difficulty and low throughput 189. When paired with calcium- or voltage-sensitive
fluorescent indicators, optical imaging allows for the simultaneous capture and analysis
of cellular signaling in diverse cell populations 198. Additionally, the development of
genetically encoded calcium indicators (GECIs), such as GCaMP6s, allows for the
spatiotemporal control of cell-type specific calcium indicator expression 298. In these
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Figure 4.1: Sensory neuron classifications and their ion channels. Sensory neurons exit the dorsal
horn of the spinal cord, through the dorsal root (DR). Cell soma reside in the dorsal root ganglion (DRG)
and can be generally classified into four sub-categories by size, conduction velocity, and protein/ion
channel expression. C-fibers are small diameter, peptidergic or non-peptidergic neurons which are
primarily implicated in the sensing of noxious stimuli. Lightly myelinated Aδ fibers are also implicated in
sensitivity to noxious thermal, mechanical, and chemical stimuli. Larger Aα and Aβ myelinated fibers
are primarily implicated in proprioception and non-noxious mechanosensation. All neuron subtypes
express a variety of ion channels (TRP, NaV, KV, CaV, etc.) which are essential for appropriate action
potential initiation and transmission, alterations in cellular expression of these ion channels can alter
functional excitability.

imaging-based approaches, calcium flux is used as a surrogate trailing measure of action
potential propagation and can be influenced by a wide variety of ion channels (Fig. 4.1).
Nevertheless, GECIs have given investigators the freedom to reliably study in vivo and in
vitro neural signaling dynamics without the need for invasive patch clamping or
exogenous dye loading199.
Following acute isolation of dorsal root ganglion (DRG) tissues by axotomy, in vitro
techniques typically require DRG dissociation by enzymatic digestion and mechanical
disruption. Prior work has shown even short-term incubation of neural cells with lowconcentration enzymatic agents, such as trypsin or papain, may reduce cell viability and
the expression of structurally and functionally relevant proteins 299. Furthermore, this
physical disruption of native tissue architecture alters the intrinsic cell-cell and cell-matrix
interactions that are present in vivo; indeed, these interactions have been shown to
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influence neuronal excitability as well as gene and protein expression 194,300,301. Long-term
monolayer culture of DRG neurons also often requires the exogenous administration of
growth factors, such as nerve growth factor and glial cell line-derived neurotrophic factor,
but these have been shown to directly impact cell phenotype 302–304. Extended culture
periods following isolation have also been shown to alter cell-cell interactions through
satellite cell proliferation; while anti-mitotic drugs may be administered in vitro to prevent
this proliferation, their use negatively impacts sensory neuron structure and
function305,306. These factors, amongst others, may influence neural cell responses in
vitro. Hence, there is a need to develop alternative in vitro methods for assessing sensory
neuron excitability in acutely isolated DRGs.
The work in this chapter describes the development of an electric field stimulation
mediated cellular imaging method for the direct interrogation of Ca2+ signaling dynamics
in intact acutely isolated DRG tissues. This method allows for the rapid and simultaneous
characterization of functional excitability in hundreds of sensory neurons. Using this
technique, we show an ability to measure dose-dependent changes to electric field
stimulated Ca2+ signaling in the presence of a voltage-gated sodium channel inhibitor
and an ability to detect differences in neuronal excitability in a peripheral nerve injury
model. Taken together, the described system shows potential for the study of
pharmacologically and injury-induced alterations to large and heterogeneous neural
populations without the need for dramatic perturbation to the DRG neurons’ native
microenvironment.
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4.2 Methods
4.2.1 Animal model
All procedures were performed with approval of the Washington University in St
Louis Institutional Animal Care and Use Committee. Transgenic Advillin-CreERT2 (Cre/+,
Stock No: 032027, The Jackson Laboratory, Bar Harbor, ME) mice were crossed with
STOP-GCaMP6s (+/-, Stock No: 028866, The Jackson Laboratory) mice 298,307. Crepositive mice received three consecutive doses of tamoxifen (i.p, daily, 75 mg/kg, SigmaAldrich, St Louis, MO) to induce GCaMP6s expression in Advillin expressing neurons
(Fig. 4.2A,B)307. GCaMP6s was chosen for its high signal to noise ratio and slower
temporal dynamics which enable its use in widefield, spinning-disk confocal, imaging.

Figure 4.2: Experimental design. (A) Sensory neuron specific expression of GCaMP6s was attained
by crossing STOP-GCaMP6s (+/-) and Advillin-CreERT2 (Cre/-) mice. (B) Robust GCaMP expression
in DRG neurons was observed 3 weeks following tamoxifen (tam, 75 mg/kg, IP, 3X) dosing. (C) Intact
DRGs were placed within an EFS recording chamber beneath a nylon mesh and were continuously
perfused with fresh artificial cerebrospinal fluid (aCSF, 2 mL/min). (D) Representative cellular traces of
the normalized GCaMP fluorescence (∆F/F) and corresponding images (E), with increasing voltage
amplitude (5-100V). The inset depicts the applied excitatory pulse train that was used at each voltage
(10 Hz, 1 ms pulse width); frames corresponding to each numbered peak are shown with color-coded
cellular regions of interest.
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Three weeks following tamoxifen dosing mice were utilized for electric field stimulation
experiments. Mice were maintained on a 12-h light-dark cycle with access to food and
water ad libitum.

4.2.2 Dorsal root ganglion (DRG) isolation
Mice were deeply anesthetized under isoflurane (3% inhalation, 2 L/min oxygen,
n=6, 16-20 wks). A transcardial perfusion was performed with artificial cerebrospinal fluid
(aCSF, 124 mM NaCl, 5 mM KCl, 20 mM HEPES, 10 mM d-glucose, 1.3 mM MgCl 2, 1.5
mM CaCl2, 26 mM NaHCO3, 1.25 mM NaH2PO4)308 after which DRGs (T13-L5) were
isolated via a dorsal approach196. Following a midline dorsal incision, paraspinal
musculature, connective tissue, and fat were carefully removed with micro-dissection
scissors to reveal the dorsal bony elements of the spine. Micro-rongeurs were then used
to perform a multi-level laminectomy to expose the spinal cord, which was gently
repositioned to expose the DRGs at each spinal level. Fine forceps were used to grasp
the distal nerve root and gently remove the DRG from the neuroforamen, and spring
scissors were used to carefully cut the nerve roots proximal and distal to the DRG.
Isolated DRGs were then incubated in aCSF and used for EFS experiments within 8 h of
isolation.

4.2.3 Electric field stimulation (EFS)
Intact DRGs were placed in the center of a recording chamber (RC-RC49MFSH,
Warner Instruments, Hamden, CT), secured by a nylon mesh, and perfused with aCSF
(2 mL/min) (Fig. 4.2C). Two parallel, linear platinum electrodes connected to a pulse
generator (Grass SD9, Natus Neuro, Warwick, RI) were inserted at opposite ends of the
recording chamber and DRGs were stimulated with bipolar square pulse waves (1 ms, 10
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Hz, 1 sec on/ 29 sec off) at voltage amplitudes of 5-100V (Fig. 4.2D); these EFS
parameters were chosen for their ability to evoke robust evoked Ca2+ transients within
intact DRGs as have been reported previously190,309–311. The geometry of the recording
chamber ensured the generation of a uniform electric field between electrodes 190. Intact
DRGs were imaged (Plan Apo λ 10X, 0.45 NA) to collect GCaMP6s fluorescence
(488/525 nm, ex/em, 10 Hz) upon a spinning disk confocal microscope (Ti2-CSU-X1,
Nikon Instruments, JPN) (Fig. 4.2E). Time series recordings at a single imaging plane
(~20 µm from tissue basal surface, 2.5 µm z-thickness) were acquired. Single recordings
were completed in 6 min; DRGs were allowed to recover within the recording chamber
for 5 min followed by a repeated exposure to EFS in order to evaluate the repeatability of
response and to confirm viability of tested neurons.

4.2.4 Tetrodotoxin inhibition
To test the ability of the described EFS imaging technique to be used for drug
screening in intact DRGs, the potent voltage-gated sodium channel (VGSC) inhibitor
tetrodotoxin (TTX, Tocris, Minneapolis, MN) was used as described here 312. DRGs
underwent one voltage sweep (5-100 V) as described, followed by incubation with
increasing concentrations of TTX (5 min incubation, 0.01-10 µM), and a repeat of the EFS
voltage sweep protocol was performed.

4.2.5 Peripheral nerve injury
Peripheral nerve injury was induced in female Advillin-GCaMP6s mice (16 wks,
n=2, [Cre/+,+/-], n=2 [+/+,+/-]) as described313,314. Mice were anesthetized under
isoflurane (1-3% inhalation, 2 L/min oxygen), and the left hindlimb was prepped with
sterile technique. A 1 cm skin incision parallel to the femur was made at the mid-thigh to
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Figure 4.3: Peripheral nerve injury. (A) Anterior view of left hindlimb (B) The biceps femoris (BF) was
bluntly dissected and retracted (arrowhead) to expose the sciatic nerve (ScN), which was tightly ligated
proximal to ScN trifurcation. (C) Chromic gut sutures were resorbed 4 weeks following surgery; however,
ligation sites and tissue damage were readily observed upon dissection (arrowheads). (QF=quadriceps
femoris, GM=gluteal muscles). Figure adapted from Kochi+. Plos One. 2013.

expose the muscle fascia and blunt dissection was used to expose the sciatic nerve below
the biceps femoris (Fig. 4.3A,B). The sciatic nerve was then tightly ligated with three
ligatures (6-0 chromic gut suture), with 1 mm spacing, proximal to the sciatic (Fig. 4.3C).
Muscle, fascia, and subcutaneous tissues were closed with 5-0 vicryl suture and skin
closed was closed with 4-0 nylon suture. Following recovery from anesthesia animals
were returned to their home cage (≤5 mice/cage) and allowed to freely ambulate.
Following nerve injury, mice were aged one month prior to use in EFS experiments which
were performed on L3-L5 DRG.

4.2.6 Hindpaw mechanical sensitivity
Hindpaw sensitivity to light-touch was evaluated bilaterally using von Frey
filaments as described in section 2.2.3.

4.2.7 Hindpaw thermal sensitivity
Hindpaw sensitivity to a hot stimulus (55°C) was tested using methods previously
described in section 2.2.5.
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4.2.8 Data analysis
Following stimulation of DRGs in the EFS chamber, digital images of DRG
responses were compiled into high-speed video format. Within a single frame
corresponding to the period preceding EFS stimulation, manual tracing of all visible cell
bodies was performed in ImageJ (NIH, Bethesda, MD). Fluorescent intensity values within
each cell region of interest (ROI) over time were exported and analyzed using a custom
MATLAB (MathWorks, Natick, MA) script. Briefly, fluorescent signal prior to each EFS
stimulation was used to calculate baseline fluorescence within each cell ROI (F 0). This
baseline value was used to calculate ∆F/F0, where ∆F is the rise in fluorescence due to
EFS at each stimulation voltage. A piecewise cubic interpolating polynomial was used to
correct for drift in baseline fluorescence with time prior to each stimulus using the local
minimum (F0) within each ROI prior to EFS. A peak-detecting algorithm was used to
detect calcium responses following each voltage stimulus, and the threshold for a positive
response was set to 20% of an individual neuron’s maximum ∆F/F 0 peak height298. This
on-off binarization of sensory neuron Ca2+ signaling, when assessed by GCaMP
fluorescence, has been previously reported by Hartung and Gold311. For each DRG, the
percent of responding neurons at each voltage amplitude was calculated by normalizing
the number of responding neurons at each amplitude by the highest number responding
across all amplitudes.
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4.2.9 Statistical analysis
All statistical analyses were performed in Prism 8 (GraphPad, San Diego, CA). A
repeated measures two-way ANOVA with Bonferroni post-hoc was used to test for
differences in percent responding cells at each voltage between trials in repeatability
experiments. A constrained sigmoidal fit was performed on population response data to
determine a half-maximal response voltage (EV50) and area under the curve (AUC) was
calculated. A paired student t-test was used to compare EV 50 and AUC values between
trials in reproducibility experiments. To test for an effect of TTX dose on cellular
responses, a repeated measures one-way ANOVA with Dunnett’s post-hoc was used to
compare EV50 and AUC values at each TTX dose to the 0 µM untreated control. A
repeated measures two-way ANOVA with Bonferroni post-hoc was used to test for
differences in behavioral outcomes at each timepoint. To test for differences in EV 50 and
AUC values amongst ipsilateral and contralateral DRGs following peripheral nerve injury
an unpaired student t-test was performed. To investigate the influence of cell size on EFS
responsiveness following TTX treatment, neurons were sorted by soma diameter into
three groups (diameter < 20 µm, 20 µm < diameter < 25 µm, diameter > 25 µm) and a
repeated measures two-way ANOVA was used to compare EV 50 values between
conditions195. Relationships between 50% withdrawal threshold in hindpaw sensitivity
trials collected prior to sacrifice and AUC were tested via linear regression followed by an
F-test. Statistical significance was set at p < 0.05.
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4.3 Results
4.3.1 EFS responses are reproducible
In DRGs harvested from Advillin-GCaMP6s mice, we identified on average more
than 200 individual GCaMP expressing soma within each imaging field (221±64).
Following EFS, an increase in GCaMP fluorescence intensity was transiently observed
(Fig. 4.4A), individual cellular responses at each voltage amplitude were well conserved
between trials (Fig. 4.4B). Neurons were largely quiescent at EFS amplitudes below 20
V, with only 2.4 and 22.3% of cells responding at EFS voltage amplitudes of 5 and 10 V
on average, respectively (Fig. 4.4C). Within reproducibility validation experiments, there
were no detectable differences in percent responsive cells at each voltage in sequential
EFS trials (Voltage p<0.0001, Trial p=0.201, n=13 DRGs with n≥113 cells per DRG).
Based on observed voltage-response behaviors, data were fit with a sigmoidal function
on logarithmically transformed voltage amplitudes, and subsequent voltage-response
data are presented as linear-log plots. Furthermore, there were no detectable differences
between EV50 (p=0.923) or AUC (p=0.252) values between individual trials (Fig. 4.4D,E).
EV50 values were on average 17.2 and 17.1 V in first and second EFS trials, respectively.
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Figure 4.4: EFS produces similar responses in serially stimulated intact DRG neurons.
(A) Neurons within intact DRG tissues showed increased GCaMP6s fluorescence shortly following EFS
(B) Representative traces of an individual neuron in sequential EFS trials, all detected responses are
marked by a closed or open circle in the first and second trials, respectively. The dotted line represents
the peak height cutoff, which is 20% of the maximum peak height. (C) In subsequent trials, DRG neurons
responded similarly to voltage sweeps, and there were no differences in the percent of responding
neurons at any voltage (Repeated measures two-way ANOVA; Voltage p<0.0001, Trial p=0.201,
mean±SEM). No significant alterations were observed in EV50 (p=0.923) (D) or AUC (p=0.252) (E)
values. Repeated measures two-way ANOVA w/ Bonferroni’s post-hoc to test for differences between
trials at each voltage amplitude, paired student t-test to test for differences between trials in EV50 and
AUC (n=13 DRG, with n ≥ 113 cells per tissue). Mean±SEM, sigmoidal fit ± 95% CI.
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4.3.2 Small molecule sodium channel inhibition reduces EFS induced
signaling
To test for an ability to use the described EFS imaging method as a drug screening
platform, DRGs (n=5 with n≥138 cells per DRG) were treated with the voltage-gated
sodium channel inhibitor, TTX. Following TTX treatment, DRG neurons showed a marked
reduction in EFS evoked Ca2+ signaling (Fig. 4.5A,B). This reduced cellular
responsiveness led to a rightward shift in the voltage-response curve with increasing
concentrations of TTX (Fig. 4.5C). A dose-dependent increase in EV 50 was observed with
increasing TTX dose (p<0.0001, Fig. 4.5D). Significantly increased EV 50 values were
observed at 1 (p=0.0006) and 10 µM (p<0.0001) TTX doses compared to the untreated
negative control. Prior to TTX treatment, the average EV 50 within DRGs was 13.4 V, with
TTX treatment these values increased to 51.5 and 60.6 V at 1 and 10 µM TTX doses,
respectively. A corresponding dose-dependent reduction in AUC values were observed
with increasing TTX dose (p<0.0001); significant reductions in AUC were observed with
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1 (p=0.0003) and 10 µM (p<0.0001) TTX doses when compared to the untreated negative
control (Fig. 4.5E). TTX-sensitive voltage-gated ion channels are expressed robustly on
soma of differing size and sensory-modality; to investigate the effect of TTX inhibition
across these neural sub-populations soma were stratified by cellular diameter. Soma size
(p=0.924) did not influence EV50 values with TTX inhibition (p=0.007) (Appendix C, Fig.
C.1).

Figure 4.5: Tetrodotoxin inhibits EFS mediated Ca2+ signaling in intact DRG neurons. (A) Post
EFS (100 V) GCaMP6s fluorescence dynamics were noticeably reduced with tetrodotoxin (TTX)
treatment, and average ∆F/F (B) values across all cellular regions of interest (n=163 for displayed
representative traces) within DRG tissues had reduced amplitude with TTX treatment. Data from one
representative DRG tissue is shown. (C) TTX incubation led to a dose dependent decrease in EFS
mediated cellular response (mean±SEM). (D) An increase in EV50 was observed at 1 (p=0.0006) and
10 µM (p<0.0001) TTX doses while AUC (E) decreased at 1 (p=0.0003) and 10 µM (p<0.0001) TTX
doses when compared to untreated controls. Repeated measures one-way ANOVA w/ Dunnett’s posthoc was used to test for differences between individual TTX doses and the untreated 0 µM control;
**=p<0.01, ****=p<0.0001. Dotted line represents 0 µM control, (n=5 DRG, with n ≥ 138 cells per DRG).
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4.3.3 Peripheral nerve injury resulted in unilateral hypoesthesia
Surgically induced nerve injury resulted in clear alterations to animal behavior
including impaired motor function upon ambulation in the injured hindlimb which began to
improve 14 days following surgery. Following peripheral nerve injury, animals exhibited a
decreased sensitivity to light touch in the ipsilateral hindpaw on days 7 (p<0.0001), 14
(p<0.0001), 21 (p=0.0011), and 28 (p<0.0005) when compared the contralateral hindpaw
(Fig 4.6A). Furthermore, an increased latency to withdrawal from a hot thermal stimulus
was observed at the ipsilateral hindpaw on days 7 (p=0.0149), 14 (p<0.0066), 21
(p<0.0001), and 28 (p=0.0022) when compared to the contralateral hindpaw (Fig 4.6B).

Figure 4.6: Surgically induced peripheral nerve injury reduces mechanical and thermal
sensitivity at the injured hindpaw. (A) Reduced mechanical sensitivity in the ipsilateral hindpaw was
observed 7 (p<0.0001), 14(p<0.0001), 21(p=0.0011), and 28 (p<0.0005) days following nerve injury
when compared to contralateral hindpaws. (B) Increased latency to withdrawal from a hot thermal
stimulus (55°C) at the ipsilateral hindpaw was observed 7 (p=0.0149), 14(p=0.0066), 21(p<0.0001), and
28 (p=0.0022) days post-injury when compared to the contralateral hindpaw. Repeated measures twoway ANOVA w/ Bonferroni’s post-hoc; *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001.
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4.3.4 EFS reveals increased voltage response threshold of ipsilateral
DRGs following peripheral nerve injury
The excitatory behaviors of ipsilateral DRG neurons were altered following
surgically induced peripheral nerve injury. A rightward shift in the voltage response curve
was observed in ipsilateral DRGs (Fig. 4.7A). A corresponding increase to EV 50
(p=0.0106) and decrease in AUC (p=0.0224) was apparent in ipsilateral DRGs when
compared to their level matched contralateral DRGs (Fig. 4.7B,C). Furthermore, reduced
sensitivity at the hindpaw corresponded with decreased AUC values (Fig. 4.7D).

Figure 4.7: EFS reveals increased voltage response threshold in ipsilateral DRGs following
peripheral nerve injury. (A) One month following nerve injury acutely isolated DRGs exhibited a
rightward shift in their voltage response behavior. (B) Ipsilateral DRGs had an increased EV50
(p=0.0106) and (C) decreased AUC (p=0.0224) values when compared to contralateral DRGs. (D)
Decreased sensitivity at the hindpaw corresponded with reduced AUC values upon ex vivo assessment
(p=0.048, F-test). Paired student t-test, *=p<0.05. Mean±SEM, sigmoidal fit±95% CI.
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4.4 Discussion
Here, we describe the development of a novel ex vivo imaging technique for the
simultaneous visualization and functional assessment of hundreds of sensory neurons in
intact DRG tissues. By utilizing genetic techniques to drive the robust expression of
GCaMP6s in Advillin-expressing neurons, we showed an ability to reproducibly capture
voltage-dependent EFS mediated signaling dynamics; furthermore, we showed an ability
to measure pharmacologically induced alterations to functional signaling upon voltage
mediated EFS. Finally, this method was shown to detect a change in ex vivo DRG
responses consistent with pain-sensitivity related behavioral changes in a surgically
induced nerve injury model. These results highlight the potential utility of the described
method.
While enzymatic digestion and mechanical dissociation of DRG neurons following
axotomy remains the gold standard preparation for in vitro experiments of isolated
sensory neurons, alterations to cellular phenotype have been documented in neurons
when plated in monolayer culture. In addition to obvious artifact introduced by cellular
dissociation, the spatial organization of individual soma and axons within the DRG are
lost with cellular isolation315. Kim and colleagues have previously shown that with nerve
injury, increased calcium signaling occurs in adjacent soma mediated in part through
CX43-expressing glial cells, an observation that is lost in dissociated cultures due to
disruption of neuron-glial cell interaction195. Furthermore, the effects of dissociation may
change with time in culture: glial cells have been shown to progressively separate from
sensory neuron soma over a one week culture period 302. Extended culture periods often
require the addition of exogenous factors, such as mitotic inhibitors or growth factors, to
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prevent over-proliferation of satellite cells and improve viability in sensory neurons,
respectively. Mitotic inhibitors have been shown to reduce antero- and retro-grade
neuronal axonal transport in vitro and animal models have shown their systemic
administration may result in chronic pain 305,316. The inclusion of supplemented growth
factors in vitro increases basal intracellular production and extracellular release of
calcitonin gene-related peptide upon stimulation. In vivo studies have also highlighted the
potential for nerve growth factor to benefit the survival of small-diameter neurons,
whereas the pro-survival effects of neurotrophin-3 have been shown in larger-diameter
proprioceptive neurons317–319. These factors may further contribute to a shift in cell
population with time in prolonged sensory neuron monolayer culture.
Prior work has shown EFS can be utilized for the simultaneous and unbiased
activation of action potentials in large numbers of sensory neurons 309,320–322. Fouillet and
colleagues utilized EFS in the development of an in vitro drug screening platform and
showed that with increasing doses of TTX, dissociated monolayer cultures of DRG
sensory neurons exhibited reduced responses to voltage-mediated stimuli, similar to the
results presented in this study309. Others have shown the importance of both high-voltagegated calcium channels and VGSCs in the generation of EFS mediated Ca2+ influx 323.
Similar work has utilized micro-electrode arrays for the in vitro assessment of various
pharmacologic modulators of neuronal activity measuring Ca2+ mobilization in response
to voltage stimuli324. We believe, however, the method shown in the current study
provides important advantages over these prior techniques for its abilities to
simultaneously assess firing rates in hundreds of cells while maintaining tissue integrity
and single-cell firing resolution. Furthermore, the described method does not require
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exogenous dye loading and instead relies on Cre-driven expression which reduces EFS
experimental prep-times and ensures fluorescence cell-type-specificity and robust
genetically encoded protein expression. This is in contrast to exogenous dye loading
which relies on non-specific diffusion-based cellular uptake or micropipette injection 197.
Surgically induced peripheral nerve injury resulted in desensitization to mechanical
and thermal stimuli at the injured hindpaw. These behavioral alterations following tight
ligation were similar to those reported following either sciatic nerve crush or
transection325–327. Following peripheral nerve injury in this model, we also observed
alterations in EFS mediated DRG neuron excitability. Others have noted reduced
transcriptional and protein level expression of voltage-gated sodium channels Nav1.1,
Nav1.6, Nav1.7, Nav1.8, and Nav1.9 in DRGs following peripheral nerve injury which may
partly explain our findings for increased EV 50 in ipsilateral DRGs328–330.
While the described method has some intrinsic benefits over standard dissociation
based protocols, DRG isolation still requires axotomy, and as a result alterations to
neuron excitability using this method are representative of somatic changes. While
alterations within the soma are linked to changes at the site of peripheral sensory
innervation, this method as described does not allow for the direct interrogation of fully
intact sensory units. A further concern is that the electrical impedance of the isolated DRG
may result in a heterogeneous electric field across the tissue. These differences,
however, are expected to have little effect given the dimensions of individual cells in
proportion to the DRG tissue. Additionally, observations in this study were consistent
across neurons within DRG of varying size.
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In conclusion, these data suggest an ability to use EFS in intact DRGs to
simultaneously study the functional signaling dynamics in hundreds of neurons with
single-cell resolution. Using the genetically encoded calcium indicator GCaMP6s together
with standard spinning-disk confocal microscopy, we were able to assess alterations to
EFS induced population responses of DRG neurons following pharmacologic modulation
and injury. Taken together, these results suggest the described imaging approach
possesses the sensitivity required for the functional assessment of DRG neuron
excitability ex vivo.
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Chapter 5
Conclusions and Future Directions
5.1 Conclusions
This dissertation aimed to better understand how traumatic joint injury, and
subsequent NF-κB activation influences the symptomatic progression of PTOA. In
Chapter 2, data highlighted the transient alterations to whole joint NF-κB signaling shortly
following non-invasive knee joint injury. Work also established the temporal presentation
of various evoked and non-evoked pain-sensitivity related behaviors including the
development of chronic allodynia as well as short term alterations to ambulation/gait.
Severe joint degeneration was also observed four months following traumatic knee joint
injury.
Given the observed changes to whole joint NF-κB signaling and pain-sensitivity
related behaviors following joint injury, we hypothesized early and local NF-κB inhibition
would attenuate symptomatic and structural disease progression. Within Chapter 3, work
described the synthesis and characterization of SF and PEG-PLGA microparticles for the
sustained release of the NF-κB inhibitor, PHA-408. Both microparticle formulations
effectively entrapped PHA-408 and exhibited sustained drug release for over two months
in vitro. Drug released from microparticles was further shown to be bioactive and reduced
inflammatory mediated signaling in an NF-κB luciferase reporter cell line. While intraarticular delivery of free PHA-408 provided a modest acute chondroprotective benefit, its
local delivery had limited influence on the development of pain-sensitivity related
behaviors, and did not reduce the extent of degenerative changes to articular cartilage at
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late timepoints following knee joint injury. Furthermore, intra-articular delivery of sustained
release formulations did not overtly impact early imaging or behavioral outcomes. Drug
clearance studies showed PHA-408 was rapidly cleared from the knee joint following local
delivery, this may explain the drugs limited influence on the outcomes measured in this
dissertation.
Together, these data provide valuable insight into the symptomatic progression of
PTOA in a non-invasive murine model. Specifically, this work serves to provide a baseline
set of pain-sensitivity related behavioral changes that future studies may further
interrogate. It also establishes the utility of this model for the study of symptomatic PTOA
given its clear behavioral phenotype and clinically relevant mechanism of disease
initiation. Finally, this work highlights the challenges of intra-articular small molecule
delivery in the disease-modifying treatment of PTOA.
Additional work in this dissertation sought to develop improved methods for the
rapid and unbiased en bloc functional assessment of DRG neurons. Work in Chapter 4
established an Advillin-GCaMP6s mouse line which was used to establish ex vivo
methods to assess sensory neuron excitability to electric field stimulation within intact
DRG tissues. The described high-throughput technique was shown to reproducibly
measure Ca2+ activity following electric field induced action potential generation. Data
further showed this method could be used to detect cellular signaling alterations in
response to peripheral nerve injury and pharmacologic ion channel inhibition. This
technique may help researchers improve an understanding of neural signaling while
retaining tissue structural organization. More generally, this approach serves as a new
tool for the rapid and large-scale ex vivo recording and assessment of neural activity.
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5.2 Future Directions
This dissertation provides additional understanding into the temporal progression
of symptomatic disease in a non-invasive murine model of PTOA. Nevertheless, the
mechanisms that contribute to both the acute and long-term development of painsensitivity related behaviors remain elusive. We hypothesized that chronic activation of
NF-κB within the injured joint would contribute to persistent pain-sensitivity related
behaviors. This, however, was not supported by the data in this dissertation. To more
closely probe how longitudinal NF-κB activity within joint tissues affects the development
of pain-sensitivity behaviors, cell-type specific transgenic approaches that modulate or
sense NF-κB activation within particular joint tissues may be of benefit 67,331,332.
Furthermore, studies targeted to investigate the symptomatic impacts of musculoskeletal
injury should make use of non-evoked behavioral assessments that minimize animal
handling and external stressors as these factors have been shown to influence
outcomes122,333.
While local delivery of PHA-408 provided no long-term benefit to joint health within
this dissertation, it remains unclear as to whether alternative dosing strategies would
provide a therapeutic benefit given the rapid onset and severity of degenerative changes
observed in this model119. Additional studies are suggested to more thoroughly
investigate the disease-modifying potential of PHA-408, and similar NF-κB inhibitors, in
the context of PTOA. Such studies may benefit from using more slowly progressing PTOA
models, or earlier endpoints in the described model, paired with more frequent drug
dosing if their goal is to highlight drug efficacy77,106,142,164,274,334.
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Although it is well established that NF-κB plays a prominent role in inflammation
and associated pain-sensitivity, pharmacologic treatment strategies that target known
upstream mediators of nociception (e.g. voltage-gated and mechanosensitive ion
channels) may be of benefit in treating symptomatic PTOA 14. Indeed, the use of ion
channel agonists such as capsaicin and resiniferatoxin have shown benefit in reducing
OA pain335,336. However, the pharmacologic modulation of other ion channels in
symptomatic OA remains a promising and understudied avenue for the analgesic
treatment of disease14,254,290,337,338. As an extension of the work in this dissertation, DRGs
were isolated from mice 4 months following knee joint injury and immunostained
(Appendix B, Supplementary Methods) for the voltage-gated sodium channels NaV1.8;
preliminary results suggested a marked increase in the pain-related ion channel when
compared to DRGs isolated from age matched uninjured controls (Appendix B, Fig. B.9).
Thus, local treatments that directly antagonize these channels may provide favorable
symptomatic relief and should be further explored in the context of this PTOA model 337,339.
Additional molecular and cellular profiling of the nervous system within this non-invasive
model is also warranted to identify novel analgesic targets in PTOA. Future studies may
utilize the novel ex vivo functional and structural (Appendix D, Fig. D.1-D.4) imaging
methods developed in this dissertation to interrogate DRG neuron sensitivity or
morphometric changes to knee joint structure following injury, respectively. If paired with
retrograde/anterograde labeling techniques, the described methods may also be used to
assess functional sensitivity and structural organization of DRG neurons known to
specifically innervate distal joint structures340,341. Together these strategies may provide
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for a more comprehensive understanding of how degenerative changes within the joint
influence nociception and could lead to improved treatments for symptomatic PTOA.
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APPENDIX A
Supplementary methods and results from Chapter 2
Joint laxity testing
Murine cadavers (male, 9-12 weeks of age, n=10) underwent cyclic compressive
loading (as described in Section 2.2.1) of a randomly assigned knee joint to induce
ligamentous injury. Hindlimbs were then dissected and scored by three blinded
investigators for anterior-posterior laxity (0=naive, 1=increased anterior-posterior laxity).
Summed scores for each joint were calculated and CTRL and INJ joint scores were
compared via a Mann Whitney test.

Correlation of longitudinal measures
To test for relationships between early NF-κB-driven luminescence and
longitudinally measured behavioral outcomes Pearson correlation coefficients were
calculated. In vivo imaging and 50% withdrawal threshold data were log-transformed
(base 10). All data were then normalized by each animals’ baseline values, represented
as the difference from baseline, and the area under the curve was calculated in early (0
to 7/8 d) and late (15 to 113 d) study windows. Data were then z-scored and Pearson
correlation coefficients were calculated. Early and late windows were chosen based on
observed NF-κB luminescence temporal dynamics.
To test for relationships between OARSI scores and early NF-κB-driven
luminescence as well as chronic behavioral changes, summed OARSI scores
(LFC+LTP+MFC+MTP) were calculated. Area under the curve was calculated within a
chronic (57 to 113 d) study window for baseline corrected behavioral measures. Data
[127]

were then z-scored and Pearson correlation coefficients were calculated. The chronic
window used in this analysis was based on previous reports of cartilage degeneration
within this model which have shown OARSI scores remain similar between 56 and 112 d
following non-invasive mechanical injury120,277.
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Figure A.1: Within groups thermal latencies are bilaterally similar. (A and B) Latency to withdrawal
from a hot (50°C) stimulus at the hindpaw in CTRL (time p<0.0001, limb p=0.123, interaction p=0.989)
and INJ (time p=0.0002, limb p=0.328, interaction p=0.228) groups. (C and D) Latency to withdrawal
from a cold (0°C) stimulus at the hindpaw in CTRL (time p<0.0011, limb p=0.707, interaction p=0.889)
and INJ (time p=0.0220, limb p=0.199, interaction p=0.493) groups. Mean±SD, repeated measures
(both factors) two-way ANOIVA.

Figure A.2: Measures of ambulation within short recording periods are highly variable. (A)
Individual distance traveled traces within a 30 min recording period highlight the highly variable
ambulatory behaviors within CTRL mice. Missing datapoint within INJ group due to animal death. (B)
Animal distance traveled within 5 minute time bins decreased over the duration of the 30 minute open
field assessment, representative data is shown from baseline assessments prior to injury, mean±SD.
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Figure A.3: Relationships between early NF-κB and behavior. Early NF-κB luminescent scores were
correlated with early and late allodynia withdrawal-scores (A) and late hyperalgesia withdrawal-scores
(B). No significant correlations between early NF-κB luminescent-scores and weight bearing- (C), hot(D), or cold-scores (E) were observed within early or late time windows. Pearson correlation coefficient,
r2, and p-values are indicated. Two datapoints in thermal correlations are missing due to instrumentation
malfunction on day 0, thus baseline corrected values could not be calculated.

Figure A.4: Relationships between NF-κB, behavior, and histological outcomes. (A) Early NF-κB
luminescent scores were correlated with terminal OARSI-scores. (B) OARSI-scores were correlated
with chronic allodynia withdrawal-scores. (C) No significant correlations between terminal OARSIscores and chronic hyperalgesia- (C), weight bearing- (D), hot- (E), or cold-scores (F) were observed.
Pearson correlation coefficient, r2, and p-values are indicated. Two datapoints in thermal correlations
are missing due to instrumentation malfunction on day 0, thus baseline corrected values could not be
calculated.
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APPENDIX B
Supplementary methods and results from Chapter 3
Dorsal root ganglia immunostaining
At the terminal timepoint, 113 days following knee joint loading, animals were
sacrificed by exsanguination and subsequently transcardially perfused with 4% PFA.
Ipsilateral lumbar level 4 dorsal root ganglia (DRG) were then isolated, post-fixed (4 h,
4°C), cryoprotected in 30% sucrose (overnight, 4°C), flash-frozen in optimal cutting
temperature compound, and cryosectioned (n=4 CTRL, n=3 INJ, n=3 INJ/Tx) at 7 µm.
Slides with the largest number of cell bodies were selected from each DRG and
underwent antigen retrieval (citrate buffer, 30 min, 90°C, pH 6.0), and permeabilization
(0.2% Triton, 20 min). Samples were then blocked in 5% goat serum + 0.2% Triton (30
min) and subsequently stained in blocking buffer with primary antibody (rabbit antiNaV1.8, 1:100, Alomone Labs, ASC-016, overnight, 4°C) or isotype (rabbit IgG) control.
Samples were then washed (3X, PBS+ 0.1% Tween20), stained with secondary antibody
(goat anti-rabbit Alexa 488, 1:300, Invitrogen, 1 h) in blocking buffer, washed (3X) again,
and nuclei were counterstained with DRAQ5 (1:1000, 10 min). Samples were then
coverslipped and imaged upon a Lecia DM6 confocal microscope at 20X (ACS APO
20x/0.60 IMM). Z-stacks (5 steps, 2.2 µm step-size) were taken of all DRG and maximum
intensity projections were used for subsequent analysis. Image analysis was performed
in ImageJ, all intact cell soma within each imaging field were manually traced (n=676
CTRL, n=367 INJ, n=311 INJ/Tx) and mean fluorescent intensity (MFI) and area were
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calculated. MFI values were then compared between groups using a one-way ANOVA
with Tukey’s post-hoc. Significance was set at p<0.05.
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Figure B.1: Repeated acute intra-articular administration of PHA-408 reduces allodynia in the
MIA injection model of arthritis. Following intra-articular injection of mono-iodoacetate (0.1 mg, MIA)
repeated intra-articular delivery of PHA-408 (0.1 µg, 0 and 48 h, Tx) reduced ipsilateral hindpaw
allodynia when compared to mice receiving a Veh injection, no sensitivity alterations were observed
between groups in contralateral (C) hindpaws. Mean±SD, repeated measures two-way ANOVA w/
Bonferroni’s post-hoc; *=p<0.05, ***=p<0.001.

Figure B.2: Reporter cell responses are stimulus- and time-dependent (A) SW982 NF-κB luciferase
reporter cell line was responsive to IL-1β and lipopolysaccharide (LPS), one-way ANOVA w/ Dunnett’s
post-hoc. (B) NF-κB-driven bioluminescent signal is increased if PHA-408 treatment is delayed following
stimulation with IL-1β (1 ng/mL). Data is normalized to IL-1β-only treated control (dotted line=mean of
non-treated wells). Mean±SD, one-way ANOVA w/ Bonferroni’s post-hoc; *=p<0.05, ***=p<0.01,
***=p<0.001.

[133]

Figure B.3: PHA-408 suspension size. (A) PHA-408 drug particles were readily visible via epifluorescent microscopy at the injected concentration (0.6 mg/mL). (B) Particle diameter was 2.09±0.53
µm. Scale bar = 20 µm.

Figure B.4: LC-MS PHA-408 tissue standard curves. Standard curves are shown for each tissue
type, the inset shows one representative lymph node sample with a ~4.5 min elution time.
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Fig. B.5: A sustained release microparticle did not improve PHA-408 concentrations within the
joint. Following one-time local delivery of PHA-408 loaded SF microparticles (50 µg PHA-408,120 MB
formulation, t=0 h), drug was not detected within (A) injected knee joint tissues 24, 48, 72, or 96 h postinjection. Peak concentration in (B) serum and (C) urine were detected 48 h post microparticle injection
(n=2-3 per timepoint). Concentrations from suspension based PHA-408 (3 µg, t=0 and 48 h) intraarticular injections are plotted for reference. Mean±SD.

Figure B.6: NF-κB activation due to intra-articular injection of PHA-408 is minimal, but not
reduced when compared to vehicle control. Naive mice received one intra-articular injection (t=0) of
either PHA-408 (3ug/5uL, n=5) or vehicle control (saline+0.1% DMSO, n=4). Intra-articular injection of
PHA-408 or vehicle led to an increase in joint localized NF-κB-driven luminescence in injected knees
when compared to contralateral (C) knees, however, local delivery of PHA-408 did not lead to a
reduction in NF-κB-driven luminescence when compared to vehicle control. Mean±SD, repeated
measures two-way ANOVA w/ Bonferroni’s post-hoc to test for differences between all treatment groups;
*=p<0.05. Dotted and solid lines represent average ROI radiance values for INJ and INJ/Tx ipsilateral
knee joints 3 days post-injury, respectively.
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Figure B.7: Small molecule NF-κB inhibition influences cell viability in a dose dependent manner.
(A) SW982 cells had reduced viability after 24 hr treatment with either PHA-408 or SC-514, a similar
effect was observed with increasing concentrations of (B) drug loaded SF microparticles. Mean±SD.

Figure B.8: Ex vivo PHA-408 treatment reduces NF-κB signaling, nitric oxide release, and sGAG
loss following an inflammatory stimulus in musculoskeletal organ cultures. (A) Experimental
timeline. (B) NF-κB luminescence over time and (C) area under curve (AUC) from murine functional
spinal unit organ cultures. (D) Nitric oxide (NO) and (E) sGAG released into media. (F) Tissue
associated sGAG. Mean±SD, one- or two-way ANOVA w/ Dunnett’s post-hoc, *=p<0.05 vs vehicle
control.
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Figure B.9: Alterations to NaV1.8 protein expression in L4 ipsilateral dorsal root ganglia neurons
with injury. At the terminal timepoint, ipsilateral dorsal root ganglia (DRG) were isolated from the L4
spinal level and stained for the voltage gated sodium channel NaV1.8. (A) Representative DRG from
CTRL, INJ, and INJ/Tx groups show increased NaV1.8 staining intensity (B) in INJ and INJ/Tx DRG,
however, INJ/Tx DRG had reduced staining intensity when compared to their untreated INJ
counterparts. (C) NaV1.8 expression was highest in smaller DRG neurons. One-way ANOVA w/ Tukey’s
post-hoc to test for differences between all groups; *=p<0.05.
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Figure B.10: Ipsilateral to contralateral comparisons. Given the study design, ipsilateral to
contralateral=C comparisons were made within each timepoint. (A) NF-κB-driven luminescence, (B)
50% withdrawal threshold, (C) escape threshold, and latency to a (D) hot or (E) cold stimulus. Repeated
measures two-way ANOVA w/ Bonferroni’s post-hoc; *=p<0.05, **=p<0.01, ****=p<0.0001.
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APPENDIX C
Supplementary results from Chapter 4

Figure C.1: Soma size does not influence neural responsiveness to EFS with TTX inhibition. (A)
Responses in neurons of varying soma size were similar across TTX concentrations. Percent response
values in each size group represent a portion of all responding neurons (mean±SEM). (B) No sizebased differences were observed in EV50 at any individual TTX concentration (TTX p=0.007, Size
p=0.924). Repeated measures two-way ANOVA; n=5 DRG, with n ≥ 138 cells per DRG.
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APPENDIX D
Optically clearing musculoskeletal tissues: methods
development and application
Introduction
The gold standard approach for assessing degeneration in musculoskeletal
tissues has long been histology227. Following a study endpoint, tissues designated for
histological evaluation must be processed following a protocol that coincides with their
ultimate embedding medium. This usually requires fixation, followed by a multiweek
decalcification process and subsequent dehydration before embedding 342. Then samples
must undergo multiple resource intensive tasks including: sectioning, staining, imaging,
and scoring343. This method has been invaluable in understanding how anatomy changes
with disease; however, biology does not exist within the confines of a several micron thick
section. As such, recent approaches have aimed to improve our three-dimensional
understanding of biology by offering new tissue processing methods that support optical
light transmission through thick tissues (“clearing”)344. By pairing old and new tissue
clearing techniques with multi-photon or light-sheet microscopy many groups have been
able to image intact samples and uncover intricacies of three-dimensional spatial biology
that were overlooked or unresolvable in micron thick sections 344–348. The majority of
clearing techniques, however, have not been developed to address the unique challenges
of musculoskeletal tissues349–353. Joints have a variety of tissue types with diverse
physical properties in close proximity which pose as hurdles to clearing and imaging intact
specimens354. However, by using a combination of clearing techniques paired with
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fluorescent small molecules it may be possible to uncover morphometric changes to the
joint following injury with an improved three-dimensional context. The work described in
this appendix establishes clearing methods that have been optimized for imaging through
musculoskeletal tissues. These methods are applied in a non-invasive murine model of
PTOA to illustrate the early changes to joint morphology following joint injury.

Methods
Optical clearing method screening
Several aqueous and non-aqueous tissue clearing methods were first screened in
porcine cartilage plugs (Fig. D.1). Plugs (4 mm diameter) were biopsied from load-bearing

Figure D.1: Clearing method development. (A) Graphical schematic of tissue clearing pipelines. (B)
Representative images of tissues in respective clearing solutions (grid = 1 mm). (C and D)
Representative SHG image stacks and MFI of signal throughout collected cartilage plug z-stacks.
Mean±SEM, n=3 plugs/group.
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regions of the tibial plateau. Transverse sections of the patellar tendon were also
collected. Following isolation, tissues were fixed in 4% PFA (4 h, 4°C) and washed in PBS
before clearing. All following steps were performed in solution volumes of roughly tentimes that of the sample of interest, 15 or 50 mL polypropylene screw-top Falcon TM tubes
are typically preferred. Aqueous. TDE: Samples cleared in 2,2’-thiodiethanol (TDE,
Sigma-Aldrich, St. Louis, MO) underwent sequential immersion in increasing
concentrations of TDE in PBS (10%, 25%, 50%, 70%, 80%, and 100% vol/vol). The final
concentration of TDE can be varied to tune its refractive index (RI) for imaging depending
on sample RI355. Similar RI tunability can be attained with SeeDB, an aqueous fructosebased

clearing

protocol356.

Non-aqueous.

Following

dehydration

in

graded

tetrahydrofuran (THF, pH 9.0, 4°C, Sigma-Aldrich) and dichloromethane (DCM, 25°C,
Sigma-Aldrich), samples were immersed in their respective clearing solution. MS:
Samples were immersed in methyl-salicylate (MS, Sigma-Aldrich) until clear, and then
mounted in MS354. BABB: Samples were placed in benzyl alcohol-benzyl benzoate
(BABB; 1:1 vol/vol, Sigma-Aldrich) until the samples were clear to the naked eye, followed
by mounting in fresh BABB, the refractive index of BABB can be tuned by varying the
BA:BB ratio357–360. DBE: Following dehydration samples were immersed in dibenzyl ether
(DBE, Sigma-Aldrich) until clear and were then mounted in fresh DBE361. Special care
should be taken when using these non-aqueous agents; polystyrene products should be
avoided.
Non-aqueous clearing methods appeared to more consistently reduce tissue
opacity in cartilage and tendon; thus, they were used in further optimization for the en
bloc imaging of murine knee joints. It has been previously reported that decalcification
[142]

and dehemification of musculoskeletal tissues may serve to reduce RI mismatch induced
photon scattering and absorption, resepecitively351,362. Therefore, we investigated how
these tissue constituents impacted an ability to resolve propidium iodide stained
chondrocytes deep within intact knee joints. Mice (12-20 weeks of age, FVB.Cg-Tg(HIVEGFP,luc)8Tsb/J, Jackson Laboratory, Bar Harbor, ME) were euthanized via
exsanguination and transcardially perfused with 4% PFA. Intact knee joints were
harvested and post-fixed overnight (4% PFA, 4°C). Tissue surrounding the joint capsule
was carefully trimmed and samples were then processed as outlined in Figure D.2A. A
subset of knee joints were decalcified with 10% ethylenediaminetetraacetic acid (EDTA,
pH 8.0, 37°C, 2 days, Sigma-Aldrich). Cell nuclei were stained with propidium iodide (PI,
10 µg/mL, 25°C, 1 day, Sigma-Aldrich)352,363. An additional group of knee joints were
treated

to

remove

heme

(“dehemed”)

in

25%

N,N,N′,N′-Tetrakis(2-

Hydroxypropyl)ethylenediamine (Quadrol + 1% Triton X-100, 37°C, 1 d, Sigma-Aldrich).
Samples were then dehydrated in graded THFs and immersed in DBE as previously
described.
To illustrate the utility of this imaging technique, a non-invasive model of PTOA
was used. Right knees of mice (12-16 weeks of age, FVB.Cg-Tg(HIV-EGFP,luc)8Tsb/J)
underwent 60 cycles of either 6 or 12 N compressive loading 29. Mice were then sacrificed
either 7 or 14 days following injury. A subset of mice undergoing 12 N loading were
sacrificed 28 days following injury. Following exsanguination (under isoflurane
anesthesia, IACUC# 19-1032) mice received a transcardial perfusion of Lectin-DyLight
649 (0.1 mg/ 100 µL, 1230/655-710 nm ex/em, Vector Labs, Burlingame, CA) to label
vascular surfaces at the time of sacrifice364–366.
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Visible light stereomicroscopy
Following clearing, tissues were immersed in their final clearing agents within a
glass petri dish and imaged via a visible light stereomicroscope (MZ125, Leica
Microsystems, Buffalo Grove, IL) to qualitatively assess clearing efficacy (grid = 1.0 mm).

Multiphoton microscopy
Cleared cartilage plugs were secured in a custom-made imaging chamber with
two-part epoxy and immersed in their respective clearing solution. Full-thickness second
harmonic generation (SHG, 880/420-460nm ex/em) images were acquired from the
superficial articular surface upon an upright multi-photon microscope (SP8 DIVE, Leica
Microsystems). All imaging parameters were kept constant between groups.
Cleared murine joints were imaged within the sagittal plane, intact joints were
mounted with the medial side of the joint facing upwards towards the imaging objective.
Serial planar images were collected from the medial collateral ligament (MCL) to a
subsequent depth of 1 mm. All imaging parameters were kept constant between groups
for clearing optimization and fluorescent PI (1045/630-660 nm, ex/em) and SHG
(1045/510-530 nm, ex/em) signals were simultaneously collected. Scanning parameters
in other images were chosen to balance image quality, scanning time, and file size.
Multiphoton imaging was performed using a long working distance multi-immersion
objective (FLUOTAR L 16x IMM CORR VISIR, NA=0.6, WD = 2.5 mm, Leica
Microsystems).

Image processing and analysis
To aid in clearing protocol screening, quantitative analyses were performed on
acquired images. The mean fluorescent intensity (MFI) at each imaging plane was
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calculated within a region of interest (ROI). The selected ROI was defined to include
articular surfaces of the femur and tibia within PI image stacks and the entire imaging
field within SHG image stacks. Degenerative changes to synovium and articular cartilage
were assessed to illustrate the potential utility of the described imaging techniques. Within
planar images of the medial anterior synovium, a synovial ROI was defined (200 x 50
µm)119. Cell nuclei within the ROI were manually counted to determine a nuclear number
per unit area and thickness of the intimal synovial layer was manually measured at five
locations within each ROI using ImageJ. Fluorescent images were also graded using a
standard synovitis scoring system by two blinded investigators 119,367.
To assess focal alteration to cartilage, chondrocyte nuclei within a manually
defined volume of interest (VOI) were segmented using an automated ImageJ code. VOIs
were defined to include all tissues within 30 µm of the medial femoral condyle superficial
surface. Following VOI segmentation images were cropped to reduce computational time.
A three-dimensional Gaussian kernel was applied (2 x 2 x 4 voxels) followed by a rolling
ball filter (20 voxel diameter) to minimize the impact of spatially varying background signal
on binarization. Images were then binarized and a three-dimensional watershed and
morphological opening (1 voxel structuring element) were used to help reduce
overconnected binarized nuclei. Centroid positions for all nuclear objects could then be
identified. A custom MATLAB script was used to calculate Euclidian centroid-centroid
distances between all nuclear objects and these data were used to determine the three
nearest neighbors of all nuclei. From these data, and observations of planar images, it
was apparent 12 N injury led to a well-conserved focal lesion within the anterior region of
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the medial femoral condyle which was more closely integrated within a smaller VOI (300
x 30 x 100 µm). Nuclei per unit volume were calculated within this VOI.

Results and Discussion
Optical clearing increased qualitative sample transparency (Fig. D.1B), less
opaque samples had increased depth-resolved SHG signal (Fig. D.1C,D). Decalcification
of intact murine joints improved sample transparency, particularly in calcified joint
structures, while heme removal had a minimal qualitative impact on sample clarity (Fig.
D.2C). Decalcified samples had a trend of increased PI (Fig. D.2E) and SHG (Fig. D.2F)

Figure D.2: Clearing optimization within murine joints. (A) Graphical schematic of generalized knee
clearing pipeline. (B) Steps and time to completion for each protocol following tissue fixation. (C)
Representative brightfield images of murine joints cleared using each protocol (grid = 1 mm). (D) Field
of view (FOV) used in subsequent sagittal plane image stacks. (E and F) Representative depth resolved
images and (G and H) quantification of propidium iodide (PI) and second harmonic generation (SHG)
images, respectively. Signal intensity within the defined region of interest (ROI) are plotted as well as a
qualitative z-depth limits of cellular and collagen morphology resolution. Mean, n=2-3 knees/group.
PM=posterior meniscus, AM=anterior meniscus, MFC=medial femoral condyle, MTP=medial tibial
plateau, MCL=medial collateral ligament, ACL=anterior cruciate ligament, PCL=posterior cruciate
ligament.
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signal at deeper imaging depths within the imaging ROI. The qualitative limit of cellular
resolution within non-decalcified samples was roughly 500 µm from the MCL, in
decalcified samples individual PI stained nuclei could be seen at imaging depths of nearly
800 µm (Fig D.2G), similarly, fibrillar collagen structures could be seen at depths of over
1000 µm from the medial collateral ligament in decalcified samples (Fig D.2H).
Furthermore, homogeneity of PI and SHG signal intensity across the imaging field was
improved in decalcified samples.
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Following knee joint injury (Fig. D.3A), joints tended to have increased synovial
thickness and planar cell density within the intimal layer of the anterior synovium (Fig.
D.3B,C). Synovitis scores were similar to those previously reported within this noninvasive loading model at early timepoints119. A modest focal reduction in threedimensional chondrocyte density was observed within the anterior region of the MFC (300
x 30 x 100 µm VOI) of 12 N loaded knee joints (Fig. D.3D-F).

Figure D.3: En bloc imaging enables structural interrogation of joint tissues through optical
sectioning. (A) Right knees underwent 6 or 12 N cyclical loading and mice were sacrificed within 14
days of knee joint injury and were subsequently cleared using a decalcification-based protocol. (B and
C) Anterior synovium of injured knee joints trended towards having increased thickness, cell nuclei per
unit area, and higher histopathological scores. (D) Representative nuclear centroid maps of the medial
femoral condyle display position and average distance to each nuclear objects’ three nearest neighbors,
the outlined region in the 12 N image highlights a focal reduction in cellularity. (E and F) Nuclear object
detection within a 30x300x100 µm volume of interest in the anterior region of the medial femoral condyle
revealed a trend of reduced cell number per unit volume in 12 N loaded joints. Mean±SD, n=3
knees/group.
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Morphological alterations to synovial vascular structures were observed 4 weeks
following knee joint injury (Fig. D.4A,B). Additional early changes to cellularity were
observed in other joint structures (e.g. posterior medial meniscus) following 12 N injury
(Fig. D.4C). The described methods were also compatible with other tools (Fig. D.4D,E)
frequently used within musculoskeletal research (e.g. fluorescent reporters, dynamic
bone labeling).

Figure D.4. Additional applications of musculoskeletal tissue clearing (A-C) Alterations in the
morphology of lectin labeled vascular structures were observed in anterior synovium 28 days following
12 N knee joint injury. Additional focal changes to knee joint cellularity were observed in knee joint
structures such as the medial meniscus within 7 days of 12 N injury. (D-E) Tissue clearing protocols
were also shown to be compatible with transgenic fluorescent reporters (murine rib and surrounding
neuro-vascular tissues, B6.Cg-Tg(Thy1-YFP)16Jrs/J mice) and dynamic bone labeling (murine calvaria,
non-decalcified).

These data suggest optical clearing may serve as a first-pass method to assess
changes in musculoskeletal tissue structures in novel animal models where the spatial
position of a phenotype may be unknown. This technique is of particular value in focal
diseases such as PTOA where different sectioning planes may show vastly different
degrees of degneration35,36. Others have emphasized this limitation of gold standard
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histopathological assessments in the context of PTOA. For example, Glasson and
colleagues highlight the high degree of degenerative changes following ACL transection
in the posterior aspect of the tibial plateau 107. These erosive changes are outside of the
typical mid-contact region which is typically assessed histologically within the coronal
plane227. Thus, sections scored from the mid-contact region within ACL transection knees
might not accurately represent the full extent of joint degeneration. Non-destructive
imaging techniques, such as those described here, may help to overcome these
limitations. Following identification of an ideal sectioning plane or region of interest,
standard histological techniques can still be used to assess morphometric, phenotypic,
and cellular changes via more well-established measures.
Despite the described benefits of clearing and en bloc imaging, the technique is
not without limitations. Clearing methods have mostly been developed to improve en bloc
imaging in soft tissues with relatively homogenous tissue constituents 349. The
heterogeneity of tissues in the joint presents several hurdles for which the developed
tissue clearing methods are unable to fully overcome. For example, the RI mismatch
between bone and DBE was apparent in non-decalcified samples where bone appeared
to be more opaque than surrounding tissues. Decalcification helps to reduce the RI of
bone thereby homogenizing the RIs within the joint space 354,368. Ultimately this reduces
the number of scattering events for incident and emitted photons and improves axial
resolution. However, there remains structural and RI inhomogeneities throughout these
cleared tissues which result in uneven illumination due to differing light-path interactions.
This makes robust quantification of acquired images difficult. For this reason, intensitybased quantification, particularly over large fields-of-view, has limited accuracy 352.
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Feedforward intelligent imaging controls may help to improve signal-to-noise by actively
modulating laser intensity and detector gain depending on previously collected imaging
data. Recent advances in deep-learning neural network based segmentation have also
sought to address these image analysis based shortcomings and have led to more
accurate quantification of such volumetric imaging datasets 369. Nevertheless, en bloc
imaging serves as a valuable companion method to investigators within the
musculoskeletal field for assessing the three-dimensional microscale changes to intact
tissues and organs without the immediate need for laborious histological techniques.
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